NZ713111B2 - Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue - Google Patents
Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue Download PDFInfo
- Publication number
- NZ713111B2 NZ713111B2 NZ713111A NZ71311114A NZ713111B2 NZ 713111 B2 NZ713111 B2 NZ 713111B2 NZ 713111 A NZ713111 A NZ 713111A NZ 71311114 A NZ71311114 A NZ 71311114A NZ 713111 B2 NZ713111 B2 NZ 713111B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- cartilage
- chondrocyte
- population
- tissue
- Prior art date
Links
- 210000004027 cells Anatomy 0.000 title claims abstract description 546
- 210000001612 Chondrocytes Anatomy 0.000 title claims abstract description 281
- 210000001519 tissues Anatomy 0.000 title claims abstract description 207
- 210000000845 Cartilage Anatomy 0.000 title claims abstract description 206
- 239000000203 mixture Substances 0.000 title description 35
- 210000003716 Mesoderm Anatomy 0.000 claims abstract description 180
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 claims abstract description 138
- 239000000556 agonist Substances 0.000 claims abstract description 127
- 101710039712 NT5E Proteins 0.000 claims abstract description 121
- 102100017063 NT5E Human genes 0.000 claims abstract description 121
- 102100015886 BMP4 Human genes 0.000 claims abstract description 96
- 101700005069 BMP4 Proteins 0.000 claims abstract description 95
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 82
- 239000003112 inhibitor Substances 0.000 claims abstract description 73
- 102100009705 ENG Human genes 0.000 claims abstract description 72
- 101710004859 ENG Proteins 0.000 claims abstract description 72
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims abstract description 71
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 68
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 68
- 229920001436 collagen Polymers 0.000 claims abstract description 67
- 102000008186 Collagen Human genes 0.000 claims abstract description 66
- 108010035532 Collagen Proteins 0.000 claims abstract description 66
- 229960005188 collagen Drugs 0.000 claims abstract description 66
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000002609 media Substances 0.000 claims abstract description 45
- 101700030874 SOX9 Proteins 0.000 claims abstract description 44
- 210000002966 Serum Anatomy 0.000 claims abstract description 36
- 102100007544 NCAM1 Human genes 0.000 claims abstract description 27
- 101700077124 NCAM1 Proteins 0.000 claims abstract description 27
- 108050003627 Wnt Proteins 0.000 claims abstract description 27
- 102000013814 Wnt Human genes 0.000 claims abstract description 27
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims abstract description 17
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims abstract description 17
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 102000008872 noggin protein Human genes 0.000 claims abstract description 12
- 108091005284 noggin protein Proteins 0.000 claims abstract description 12
- 101710003421 FGF Proteins 0.000 claims description 62
- 239000000126 substance Substances 0.000 claims description 60
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 41
- 230000004069 differentiation Effects 0.000 claims description 39
- 230000001939 inductive effect Effects 0.000 claims description 35
- 210000001811 Primitive Streak Anatomy 0.000 claims description 34
- 230000001969 hypertrophic Effects 0.000 claims description 33
- 102100019040 PRG4 Human genes 0.000 claims description 32
- 108010009030 lubricin Proteins 0.000 claims description 28
- 238000004166 bioassay Methods 0.000 claims description 27
- 238000000684 flow cytometry Methods 0.000 claims description 24
- 210000000988 Bone and Bones Anatomy 0.000 claims description 22
- 230000011664 signaling Effects 0.000 claims description 20
- 230000035755 proliferation Effects 0.000 claims description 18
- 101700002602 MEOX1 Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 238000004264 monolayer culture Methods 0.000 claims description 13
- 239000000969 carrier Substances 0.000 claims description 12
- 239000000411 inducer Substances 0.000 claims description 12
- 101710012044 NKX3-2 Proteins 0.000 claims description 11
- 102000003995 transcription factors Human genes 0.000 claims description 10
- 108090000464 transcription factors Proteins 0.000 claims description 10
- FABQUVYDAXWUQP-UHFFFAOYSA-N 4-N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims description 9
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 210000002242 Embryoid Bodies Anatomy 0.000 claims description 8
- -1 FGF8a Proteins 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 claims description 7
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 7
- 210000001671 Embryonic Stem Cells Anatomy 0.000 claims description 7
- YSFTYXKQUONNFY-NQXPEFQPSA-N FGF2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 claims description 7
- 102100007406 FGF4 Human genes 0.000 claims description 7
- 101700036125 FGF4 Proteins 0.000 claims description 7
- 102100015612 FGF9 Human genes 0.000 claims description 7
- 101700084870 FGF9 Proteins 0.000 claims description 7
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 claims description 7
- 102100002456 TGFB2 Human genes 0.000 claims description 7
- 101700020851 TGFB2 Proteins 0.000 claims description 7
- 101700071614 WNT3A Proteins 0.000 claims description 7
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims description 6
- 239000000316 bone substitute Substances 0.000 claims description 6
- 101700000123 BMP2 Proteins 0.000 claims description 5
- 101700031714 HES2 Proteins 0.000 claims description 5
- 102100004108 HES2 Human genes 0.000 claims description 5
- 102000004338 Transferrin Human genes 0.000 claims description 5
- 108090000901 Transferrin Proteins 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000012581 transferrin Substances 0.000 claims description 5
- 102100007311 BMP10 Human genes 0.000 claims description 4
- 101700058635 BMP10 Proteins 0.000 claims description 4
- 102100005377 BMP2 Human genes 0.000 claims description 4
- 102100015880 BMP6 Human genes 0.000 claims description 4
- 101700086945 BMP6 Proteins 0.000 claims description 4
- 102100015882 BMP7 Human genes 0.000 claims description 4
- 101700060441 BMP7 Proteins 0.000 claims description 4
- 102100000137 CILP2 Human genes 0.000 claims description 4
- 101700006365 CILP2 Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- 101710012882 NKX2-5 Proteins 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 108010008846 chordin Proteins 0.000 claims description 4
- 102000006533 chordin Human genes 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 101710026724 ACVR1B Proteins 0.000 claims description 3
- 102100000003 ACVR1B Human genes 0.000 claims description 3
- 101710026725 ACVR1C Proteins 0.000 claims description 3
- 102100000004 ACVR1C Human genes 0.000 claims description 3
- 102100008645 FGF3 Human genes 0.000 claims description 3
- 102100007408 FGF5 Human genes 0.000 claims description 3
- 101700010264 FGF5 Proteins 0.000 claims description 3
- 102100007407 FGF6 Human genes 0.000 claims description 3
- 101700012851 FGF6 Proteins 0.000 claims description 3
- 101710004181 INTS2 Proteins 0.000 claims description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 Dexamethasone Drugs 0.000 claims description 2
- 210000002889 Endothelial Cells Anatomy 0.000 claims description 2
- 102100015608 FGF16 Human genes 0.000 claims description 2
- 101700001153 FGF16 Proteins 0.000 claims description 2
- 102100015617 FGF17 Human genes 0.000 claims description 2
- 101700000156 FGF17 Proteins 0.000 claims description 2
- 102100015616 FGF18 Human genes 0.000 claims description 2
- 101700001573 FGF18 Proteins 0.000 claims description 2
- 102100015614 FGF19 Human genes 0.000 claims description 2
- 101700047578 FGF19 Proteins 0.000 claims description 2
- 102100007142 FGF20 Human genes 0.000 claims description 2
- 101700028871 FGF20 Proteins 0.000 claims description 2
- 101700036284 FGF23 Proteins 0.000 claims description 2
- 102100008636 FGF23 Human genes 0.000 claims description 2
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 2
- 102000015735 beta Catenin Human genes 0.000 claims description 2
- 108060000903 beta Catenin Proteins 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 102000003973 fibroblast growth factor 21 Human genes 0.000 claims description 2
- 108090000376 fibroblast growth factor 21 Proteins 0.000 claims description 2
- 102100000360 FGF13 Human genes 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 43
- 102100004939 PDGFRB Human genes 0.000 abstract description 31
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 abstract description 31
- 239000004017 serum-free culture media Substances 0.000 abstract description 13
- 102100015284 DKK1 Human genes 0.000 abstract description 10
- 101700029587 DKK1 Proteins 0.000 abstract description 10
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 abstract description 8
- 230000014509 gene expression Effects 0.000 description 85
- 210000004349 Growth Plate Anatomy 0.000 description 37
- 210000001188 Cartilage, Articular Anatomy 0.000 description 36
- 230000001605 fetal Effects 0.000 description 27
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 201000008482 osteoarthritis Diseases 0.000 description 22
- 238000000338 in vitro Methods 0.000 description 18
- 210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 102100008634 FGF2 Human genes 0.000 description 15
- 101700082364 FGF2 Proteins 0.000 description 15
- 206010020880 Hypertrophy Diseases 0.000 description 15
- 102100014320 TGFB1 Human genes 0.000 description 15
- 101700041213 TGFB1 Proteins 0.000 description 15
- 230000001058 adult Effects 0.000 description 15
- 210000001704 mesoblast Anatomy 0.000 description 15
- 230000002648 chondrogenic Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 description 13
- 108090000193 Interleukin-1 beta Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000005755 formation reaction Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- GEDVVYWLPUPJJZ-UHFFFAOYSA-N (7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride Chemical compound [Cl-].N1=C2C=CC(=[N+](C)C)C=C2SC2=C1C=C(C)C(N)=C2 GEDVVYWLPUPJJZ-UHFFFAOYSA-N 0.000 description 10
- 102100003274 GDF5 Human genes 0.000 description 10
- 101700016442 GDF5 Proteins 0.000 description 10
- 108010067787 Proteoglycans Proteins 0.000 description 10
- 102000016611 Proteoglycans Human genes 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 229950003937 tolonium Drugs 0.000 description 10
- DDLZLOKCJHBUHD-WAVHTBQISA-N 6-bromoindirubin-3'-oxime Chemical compound O=C/1NC2=CC(Br)=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 108010059616 Activins Proteins 0.000 description 8
- 102100008240 INHBE Human genes 0.000 description 8
- 102400000817 P-beta Human genes 0.000 description 8
- 101800000616 P-beta Proteins 0.000 description 8
- 239000000488 activin Substances 0.000 description 8
- 108010023082 activin A Proteins 0.000 description 8
- 230000001464 adherent Effects 0.000 description 8
- 230000003042 antagnostic Effects 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000003827 upregulation Effects 0.000 description 8
- 101700035175 AHL27 Proteins 0.000 description 7
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 7
- 210000002304 ESC Anatomy 0.000 description 7
- 210000002744 Extracellular Matrix Anatomy 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 7
- 102100013180 KDR Human genes 0.000 description 7
- 101700033678 KDR Proteins 0.000 description 7
- 101710030888 KDR Proteins 0.000 description 7
- 230000033558 biomineral tissue development Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108010054624 red fluorescent protein Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 101710038910 COL2A1 Proteins 0.000 description 6
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 6
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 6
- 101710018349 PDGFRA Proteins 0.000 description 6
- 102100004940 PDGFRA Human genes 0.000 description 6
- 230000002730 additional Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000002317 cardiac myocyte Anatomy 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 210000000577 Adipose Tissue Anatomy 0.000 description 5
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 5
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 5
- 102100018351 COL2A1 Human genes 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 5
- 108010041390 Collagen Type II Proteins 0.000 description 5
- 102000028959 Collagen Type X Human genes 0.000 description 5
- 108010022510 Collagen Type X Proteins 0.000 description 5
- 210000003127 Knee Anatomy 0.000 description 5
- 108010078762 Protein Precursors Proteins 0.000 description 5
- 102000014961 Protein Precursors Human genes 0.000 description 5
- 108009000607 Wnt Signaling Proteins 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 230000001681 protective Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000004450 types of analysis Methods 0.000 description 5
- 208000003432 Bone Disease Diseases 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 4
- 101710027973 PLPPR2 Proteins 0.000 description 4
- 101700020998 PRG4 Proteins 0.000 description 4
- 102100018792 SP7 Human genes 0.000 description 4
- 210000002023 Somites Anatomy 0.000 description 4
- 101700022654 WNT9A Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000022159 cartilage development Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000002458 cell surface marker Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 102100002944 ACAN Human genes 0.000 description 3
- 102100010560 ADAMTS4 Human genes 0.000 description 3
- 108091005656 ADAMTS4 Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 239000004132 Calcium polyphosphate Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000001267 GSK3 Human genes 0.000 description 3
- 108060006662 GSK3 Proteins 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 208000009883 Joint Disease Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229960002429 Proline Drugs 0.000 description 3
- 101700025421 RUNX2 Proteins 0.000 description 3
- 102100013037 RUNX2 Human genes 0.000 description 3
- 101700023803 SP7 Proteins 0.000 description 3
- 102100015249 VEGFA Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 235000019827 calcium polyphosphate Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000011227 chondrocyte hypertrophy Effects 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 238000003571 reporter gene assay Methods 0.000 description 3
- LBPKYPYHDKKRFS-UHFFFAOYSA-N 2-[5-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl]-1,5-naphthyridine Chemical compound CC1=CC=CC(C2=C(C=NN2)C=2N=C3C=CC=NC3=CC=2)=N1 LBPKYPYHDKKRFS-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 101710041006 ACAN Proteins 0.000 description 2
- 108091005655 ADAMTS5 Proteins 0.000 description 2
- 102000006741 ADAMTS5 Protein Human genes 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 101700054359 ALPL Proteins 0.000 description 2
- 102100013691 ALPL Human genes 0.000 description 2
- 101700010212 ASF1A Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- 101710011399 COL10A1 Proteins 0.000 description 2
- 102100004133 COL10A1 Human genes 0.000 description 2
- 206010061762 Chondropathy Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 2
- 108009000074 Endochondral Ossification Proteins 0.000 description 2
- 210000001900 Endoderm Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091008101 FGF receptors Proteins 0.000 description 2
- 102000027757 FGF receptors Human genes 0.000 description 2
- 102100008658 FN1 Human genes 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- 210000001503 Joints Anatomy 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100004244 LIN28A Human genes 0.000 description 2
- 101710032940 LIN28A Proteins 0.000 description 2
- 102100014894 MMP2 Human genes 0.000 description 2
- 101700060512 MMP2 Proteins 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 2
- WRKPZSMRWPJJDH-UHFFFAOYSA-N N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]acetamide Chemical compound S1C2=CC(C)=CC=C2N=C1NC(=O)CSC1=NC=2CCSC=2C(=O)N1C1=CC=CC=C1 WRKPZSMRWPJJDH-UHFFFAOYSA-N 0.000 description 2
- 208000008558 Osteophyte Diseases 0.000 description 2
- 108091007929 PDGF receptors Proteins 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M Rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 102100015788 SOX9 Human genes 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100002577 WNT9A Human genes 0.000 description 2
- 229940121396 Wnt pathway inhibitors Drugs 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 230000035194 endochondral ossification Effects 0.000 description 2
- 230000037320 fibronectin Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- 238000001711 protein immunostaining Methods 0.000 description 2
- 238000003530 single readout Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- KWTQSFXGGICVPE-WCCKRBBISA-N (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- AJVRSHNXSHMMCH-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);hydrate Chemical compound O.[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O AJVRSHNXSHMMCH-UHFFFAOYSA-K 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 238000010146 3D printing Methods 0.000 description 1
- 208000008919 Achondroplasia Diseases 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 229960003767 Alanine Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 102100005375 BMP3 Human genes 0.000 description 1
- 101700001588 BMP3 Proteins 0.000 description 1
- 229920000195 Bacterial small RNA Polymers 0.000 description 1
- 210000002459 Blastocyst Anatomy 0.000 description 1
- 210000004703 Blastocyst Inner Cell Mass Anatomy 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100011820 CDKN3 Human genes 0.000 description 1
- 101700087043 CDKN3 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007709 Cartilage disease Diseases 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229940045110 Chitosan Drugs 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 229960002433 Cysteine Drugs 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108009000133 Differentiation Pathway Proteins 0.000 description 1
- 102100003763 ERG Human genes 0.000 description 1
- 101700055371 ERG Proteins 0.000 description 1
- 210000003981 Ectoderm Anatomy 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101700001948 F2R Proteins 0.000 description 1
- 102100000261 FGF10 Human genes 0.000 description 1
- 101700052889 FGF10 Proteins 0.000 description 1
- 102100007405 FGF7 Human genes 0.000 description 1
- 101700033323 FGF7 Proteins 0.000 description 1
- 102100015613 FGF8 Human genes 0.000 description 1
- 101700012405 FGF8 Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 210000000968 Fibrocartilage Anatomy 0.000 description 1
- 102100010135 GDF6 Human genes 0.000 description 1
- 101700040898 GDF6 Proteins 0.000 description 1
- 102100010137 GDF7 Human genes 0.000 description 1
- 101700021567 GDF7 Proteins 0.000 description 1
- 241000197200 Gallinago media Species 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 210000001654 Germ Layers Anatomy 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229960002449 Glycine Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229910003597 H2SeO3 Inorganic materials 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- 229960002885 Histidine Drugs 0.000 description 1
- 102000012808 Homeobox Protein Nkx-2.5 Human genes 0.000 description 1
- 108010090007 Homeobox Protein Nkx-2.5 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 101700085508 KCNH2 Proteins 0.000 description 1
- 101700011826 KCNH6 Proteins 0.000 description 1
- 101700048573 KLF4 Proteins 0.000 description 1
- 102100006525 KLF4 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N L-Asparagine Natural products OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L Molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 102100000987 NID1 Human genes 0.000 description 1
- 229910003424 Na2SeO3 Inorganic materials 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000007656 Osteochondritis Dissecans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 101710008068 POU4F1 Proteins 0.000 description 1
- 102100019166 POU4F1 Human genes 0.000 description 1
- 210000003460 Periosteum Anatomy 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101700006931 SOX2 Proteins 0.000 description 1
- 102100018829 SOX2 Human genes 0.000 description 1
- 101700077397 SOX5 Proteins 0.000 description 1
- 101700054913 SOX6 Proteins 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N Selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- 229910002850 SnCl2 Inorganic materials 0.000 description 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 102100002495 TBX18 Human genes 0.000 description 1
- 101700070567 TBX18 Proteins 0.000 description 1
- 101700027980 TCF15 Proteins 0.000 description 1
- 102100014186 TCF15 Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229960004799 Tryptophan Drugs 0.000 description 1
- 229960004441 Tyrosine Drugs 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 102100009661 VTN Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100010162 WNT3A Human genes 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L Zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910006213 ZrOCl2 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 101710026821 agnogene Proteins 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001195 anabolic Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 201000008804 arthropathy Diseases 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001269 cardiogenic Effects 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000001925 catabolic Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910052803 cobalt Inorganic materials 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003176 fibrotic Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- PVADDRMAFCOOPC-UHFFFAOYSA-N germanium monoxide Inorganic materials [Ge]=O PVADDRMAFCOOPC-UHFFFAOYSA-N 0.000 description 1
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 230000003458 metachromatic Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000007758 minimum essential media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 101700034118 myca Proteins 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000000790 osteoblast Effects 0.000 description 1
- 201000009859 osteochondrosis Diseases 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 1
- 230000008681 somite development Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 238000011099 tissue engineering Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 231100000164 trypan blue assay Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- IPCAPQRVQMIMAN-UHFFFAOYSA-L zirconyl chloride Chemical compound Cl[Zr](Cl)=O IPCAPQRVQMIMAN-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
Abstract
method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue. ptionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.
Description
TGFbeta3 agonist for an extended period of me to produce an arcular like non-hypertrophic
chondrocyte cells and/or carlage like ssue; or ii. culturing the high cell density Sox9+ collagen2+
chondrocyte precursor populaon with a BMP4 agonist for an extended period of me to produce
a hypertrophic chondrocyte like cells and/or carlage like ssue.
Title: METHODS AND COMPOSITIONS FOR GENERATING CHONDROCYTE LINEAGE CELLS
AND/OR CARTILAGE LIKE TISSUE
This is a Patent Cooperation Treaty Application which claims the benefit of 35 U.S.C. § 119
based on the priority of U.S. Provisional Patent Application No. 61/809,050, filed April 5, 2013 which
is incorporated herein by reference in its entirety.
Field
The disclosure relates to methods for producing chondrocytes and cartilage and particularly
articular chondrocytes and articular cartilage like tissue as well as hypertrophic chondrocytes and
growth plate cartilage resembling tissue from human pluripotent stem cells.
Background
The ability to efficiently and reproducibly generate differentiated cell types from
pluripotent stem cells in vitro has opened the door for the development of cell-based therapies for the
treatment of a broad range of degenerative and debilitating diseases. Osteoarthritis (OA) is a
candidate for such therapy as it affects at least one in ten adults (Lawrence, Felson et al. 2008),
leaving patients with a poor quality of life due to pain associated with joint movement. Pathogenic
hallmarks of OA include the degradation of the extracellular matrix (ECM) of articular cartilage that
lines the joints together with thickening of the underlying subchondral bone and the formation of
osteophytes (bone spurs). Articular cartilage is generated by a distinct subpopulation of chondrocytes
known as articular chondrocytes (ACs) that are specified early in development and persist throughout
adult life. While ACs function to maintain integrity of the articular cartilage under normal
circumstances, they display little capacity to repair cartilage damaged by injury or disease.
Consequently, with disease progression, damage to the cartilage is so extensive that surgical
intervention such as joint replacement is often required to improve the quality of life for the patient.
ACs differ from growth plate chondrocytes (GPCs), whose primary function is to form bone through
the process of endochondral ossification (Colnot, 2005). Interestingly, with the onset of OA, ACs
appear to acquire some characteristics of GPCs, including hypertrophy, which may contribute to the
pathogenesis of this disease.
[0004] Chondrocyte and cartilage replacement represent a potential new therapy for OA that
could, at some point dramatically reduce the need for mechanical devices. This type of therapy,
however, is dependent on access to appropriate tissue and sufficient numbers of highly enriched ACs.
It is well established that adult mesenchymal stem cells (MSCs) are able to differentiate to
chondrocytes in vitro, however, it is unclear if they are able to give rise to ACs as the cartilage-like
40 tissue generated from them prematurely undergoes hypertrophy (Pelttari, Winter et al. 2006, Steinert,
Ghivizzani et al. 2007, Pelttari, Steck et al. 2008) Alternatively, ACs have been harvested directly from
patients and used for tissue generation ex vivo, despite their limited capacity to proliferate. Tissue
generated by passaged chondrocytes exhibits fibrocartilage characteristics, which can improve the
quality of life for the patient in the short term but ultimately undergoes degradation as it lacks sufficient
weight bearing capacity (Tins, McCall et al. 2005, LaPrade, Bursch et al. 2008). Pluripotent stem cells
(PSCs) such as embryonic and induced pluripotent stem cells (ESCs, iPSCs) may represent a novel
and potentially unlimited source of chondrocytes and tissues for therapeutic applications as these
cells are able to generate a broad spectrum of cell types under appropriate conditions in vitro.
Chondrocytes develop from paraxial mesoderm that is induced in the early embryo in
an ordered temporal pattern following the generation of lateral plate mesoderm (LPM) fated to give
rise to hematopoietic and cardiovascular lineages (Lawson, Meneses et al. 1991, Kinder, Tsang et al.
1999). Following induction, strips of paraxial mesoderm are segmented into somites (Tam and Tan
1992, Kulesa and Fraser 2002). Somite development is regulated, in part, by the transcription factors
paraxis (TCF15) and TBX18, whose expression coincides with induction of paraxial mesoderm
(Burgess, Rawls et al. 1996, Bussen, Petry et al. 2004, Singh, Petry et al. 2005). Individual somites
are then patterned into the ventral sclerotome, which forms the axial skeleton, including cartilage and
the vertebral column, and the dorsal dermomyotome which develops into skeletal muscles and the
dermis of the back (Hirsinger, Jouve et al. 2000). Specification of the sclerotome is marked by the
expression of two transcription factors, Meox1 (Mankoo, Skuntz et al. 2003) and Nkx3.2 (Bapx1). A
population of collagen 2 (Col2a1) positive mesenchymal cells with chondrogenic potential develops
from sclerotome-derived cells at E12.5 of mouse development (Akiyama, Chaboissier et al. 2002,
Dao, Jonason et al. 2012).
While methods for differentiating progenitor cells to the chondrogenic lineage are
established, the ability to specify ACs, and ultimately stable cartilage tissue containing non-
hypertrophic chondrocytes, remains poorly understood. ACs are derived from interzone cells, a fibrotic
population of cells that forms at future sites of synovial joints, marked by the upregulation of Wnt9a/14
and growth and differentiation factor 5 (GDF5/BMP14), a member of the TGFß superfamily (Archer,
Dowthwaite et al. 2003, Pacifici, Koyama et al. 2006). Lineage tracing studies have shown that GDF5-
expressing interzone cells give rise to several joint tissues including ACs, but do not contribute to the
GPC population (Koyama, Shibukawa et al. 2008). GPCs, by contrast, develop from the condensing
chondrogenic mesenchyme and express BMP 2, 4 and 7, as well as hypertrophy related genes
including collagen 10. Distinct regions of ACs and GPCs are observed as early as postnatal day 7-8
when the secondary ossification center begins to form (Murakami, Balmes et al. 2004, Blumer,
Longato et al. 2007). These observations suggest that ACs and GPCs are generated from separate
progenitor populations during development and as such, may represent distinct lineages.
A number of studies have demonstrated that it is possible to derive chondrocytes
40 from mouse (m) and human ESCs and iPSCs in vitro. Most, however, used serum-based media to
support the early stages of differentiation resulting in the generation of mixed lineage end stage
cultures (Kramer, Hegert et al. 2000, zur Nieden, Kempka et al. 2005, Hwang, Kim et al. 2006,
Hwang, Varghese et al. 2008, Jukes, Both et al. 2008, Yamashita, Krawetz et al. 2008). Recent
studies have reported the use of defined culture media with specific pathway agonists and
antagonists to direct differentiation (Nakayama, Duryea et al. 2003, Darabi, Gehlbach et al. 2008,
Tanaka, Jokubaitis et al. 2009). In mESCs, Tanaka et al (2009) showed that the combination of Wnt
signaling with BMP inhibition resulted in the generation of paraxial mesoderm with chondrogenic
potential, identified by the expression of PDGFRalpha and a lack of expression of Flk-1. This
mesoderm also displayed some cardiac potential but showed no capacity to generate hematopoietic
cells indicating that dependency on BMP signaling distinguishes different types of mesoderm.
Oldershaw et al. (Oldershaw, Baxter et al. 2010) used a serum free protocol. No
tissues were obtained in vitro or in vivo with the method of Oldershaw.
[0009] Umeda et al (Umeda, Zhao et al. 2012) used a method using PDGF stimulation that
produced nodules comprising Runx2 expressing cells.
Osteoarthritis is a degenerative disease that mainly affects the joint-lining articular
cartilage of the joint. Articular cartilage has very limited capacity to regenerate itself upon injury, thus
cell and tissue replacement strategies are the only means of replacing this tissue effectively. Methods
of producing human cartilage from pluripotent stem cells are currently lacking, despite great need for
such tissues for drug discovery and cartilage replacement strategies in patients with joint diseases
such as osteoarthritis.
The object of the invention is to go at least some way to meeting this need, or to at
least provide the public with a useful choice.
Summary
In a first aspect, the invention provides a method for generating:
articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both; or hypertrophic
chondrocyte-like cells, cartilage-like tissue, or both;
the method comprising:
a. culturing a CD56 and PDGFRα primitive streak-like mesoderm population generated from
a pluripotent stem cell (PSC) population induced to differentiate into primitive streak-like
mesoderm, with a paraxial mesoderm specifying cocktail comprising an FGF agonist
selected from FGF2, FGF4, FGF9, FGF19, FGF21, FGF3, FGF5, FGF6, FGF8a, FGF16,
FGF17, FGF18, FGF20 and FGF23 for between 4-15 days following the induction of the
PSC population wherein, from between 4-6 days following induction, the paraxial mesoderm
specifying cocktail further comprises a BMP inhibitor selected from Noggin, LDN-193189,
Dorsomorphin, Chordin, soluble BMPR1a, or soluble BMPR1b, to generate a
+ + + + + + +
CD73 CD105 , CD73 PDGFRβ , or CD73 CD105 PDGFRβ paraxial mesoderm
40 population;
b. culturing the paraxial mesoderm population at a high cell density with at least one TGFβ
agonist selected from TGFβ3, TGFβ2, and TGFβ3 for at least 3 days, 3 to 7 days, or 3 to 14
days to produce a high cell density Sox9 , collagen 2 chondrocyte precursor population;
c. either:
i. further culturing the high cell density Sox9 , collagen 2 chondrocyte precursor
population with the TGFβ agonist in the absence of a BMP or PDGF agonist for at
least 10 days to produce an articular-like non-hypertrophic chondrocyte cells,
cartilage-like tissue, or both; or
ii. further culturing the high cell density Sox9 , collagen 2 chondrocyte precursor
population with a BMP4 agonist selected from BMP4, BMP2, BMP6, BMP7 and
BMP10 for at least 3 to 4 weeks to produce a hypertrophic chondrocyte-like cells,
cartilage-like tissue, or both.
In a second aspect the invention provides a method of assessing a candidate
articular chondrocyte proliferation-inducer comprising:
a. obtaining articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both
generated according to the method of any one of claims 1 to 3;
b. culturing the articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both
with a test substance;
c. measuring the articular-like non-hypertrophic chondrocyte-like cell proliferation; and
d. detecting an increase in proliferation compared to articular-like non-hypertrophic
chondrocyte cells, cartilage-like tissue, or both cultured in the absence of the test substance
indicating that the test substance is a candidate articular chondrocyte proliferation-inducer.
In a third aspect the invention provides a method of assessing a candidate
hypertrophic chondrocyte proliferation-inducer comprising:
a. obtaining hypertrophic chondrocyte-like cells, cartilage-like tissue, or both, generated
according to the method of any one of claims 1, 2, and 4;
b. culturing the hypertrophic chondrocyte-like cells, cartilage-like tissue, or both, with a test
substance;
c. measuring hypertrophic chondrocyte cell proliferation; and
d. detecting an increase in proliferation compared to hypertrophic chondrocyte-like cells,
cartilage-like tissue, or both, cultured in the absence of the test substance indicating that the test
substance is a candidate hypertrophic chondrocyte proliferation-inducer.
An aspect described herein provides a method for generating chondrocyte lineage
40 cells and/or cartilage like tissue, optionally articular like non-hypertrophic chondrocyte cells and/or
cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method
comprising:
(a) culturing a primitive streak-like mesoderm cell population (e.g. stage 2), optionally a
CD56+, PDGFRalpha+ primitive streak-like mesoderm cell population, with a paraxial
mesoderm specifying cocktail comprising:
(i) a FGF agonist;
(ii) a BMP inhibitor, optionally Noggin, LDN-193189, and/or Dorsomorphin; and
(iii) optionally one or more of a TGFbeta inhibitor, optionally SB431542; and a
Wnt inhibitor, optionally IWP2 (N-(6-Methylbenzothiazolyl)[(3,4,6,7-
tetrahydrooxophenylthieno[3,2-d]pyrimidinyl)thio]-acetamide; Sigma);
Dickkopf-related protein 1 (DKK1; R & D Systems), and/or XAV939 (3,5,7,8-
Tetrahydro[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidinone;
Sigma);
to specify a paraxial mesoderm cell population expressing cell surface CD73, CD105
and/or PDGFR-beta;
(b) generating a chondrocyte precursor population from the paraxial mesoderm cell
population expressing cell surface CD73, CD105 and/or PDGFR-beta, the generating
the chondrocyte precursor population comprising:
(i) culturing the paraxial mesoderm cell population expressing cell surface
CD73, CD105 and/or PDGFR-beta at a high cell density in serum free or
serum containing media;
(ii) culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial
mesoderm cell population with a TGFbeta agonist, optionally TGFB1, TGFB2
and/or TGFB3 in serum free media to produce a high cell density Sox9+,
collagen 2+ chondrocyte precursor population (e.g. Stage 3); and
(c) either:
(i) culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor
population with a TGFbeta agonist (optionally TGFBeta1, TGFbeta2 and/or
TGFBeta3) for an extended period of time to produce articular like non-
hypertrophic chondrocyte like cells and/or cartilage like tissue; or
(ii) culturing the high cell density Sox9+ collagen2+ chondrocyte precursor
population with a BMP4 agonist for an extended period of time to produce
hypertrophic chondrocyte like cells and/or cartilage like tissue (e.g. stage 4).
Another aspect described herein includes a method for generating chondrocyte like
cells and/or cartilage like tissue, optionally articular like non-hypertrophic chondrocyte like cells and/or
cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method
comprising:
40 (a) culturing a starting population of pluripotent stem cells with a primitive streak inducing
cocktail to induce a primitive streak-like mesoderm cell population expressing CD56
and/or PDGFR-alpha (e.g. stage 1);
(b) culturing the primitive streak-like mesoderm cell population expressing CD56 and
PDGFR-alpha with a paraxial mesoderm specifying cocktail comprising:
(i) a FGF agonist;
(ii) a BMP inhibitor, optionally Noggin, LDN-193189, and/or Dorsomorphin; and
(iii) one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor,
optionally DKK1, IWP2 and/or XAV939;
to specify a paraxial mesoderm cell population expressing cell surface CD73, CD105
and PDGFR-beta;
(c) generating a chondrocyte precursor population from the paraxial mesoderm cell
population expressing cell surface CD73, CD105 and/or PDGFR-beta, the generating
the chondrocyte precursor population comprising:
(i) culturing the paraxial mesoderm cell population expressing CD73, CD105
and/or PDGFR-beta at a high cell density in serum free or serum containing
media;
(ii) culturing the high cell density CD73+, CD105+ and PDGFRbeta+ paraxial
mesoderm cell population with a TGFbeta agonist in serum free media to
produce a high cell density Sox9+, collagen 2+ chondrocyte precursor
population; and
(d) either
(i) culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor
population with a TGFbeta agonist for an extended period of time to produce
articular like non-hypertrophic chondrocyte like cells and/or cartilage like
tissue; or
(ii) culturing the high cell density Sox9+ collagen2+ chondrocyte precursor
population with a BMP4 agonist for an extended period of time to produce
hypertrophic chondrocyte like cells and/or cartilage like tissue.
In an embodiment, the method is for generating articular like non-hypertrophic
chondrocyte like cells and/or cartilage like tissue. In another embodiment, the method is for
generating hypertrophic chondrocyte like cells and/or cartilage like tissue.
In an embodiment, the extended period of time the high cell density Sox9+
collagen2+ chondrocyte precursor population is cultured with the TGF beta agonist is at least 3
weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at
least 9 weeks, at least 10 weeks, at least 11 weeks, at least 12 weeks or more to generate a non-
hypertrophic chondrocyte like and/or cartilage like tissue that expresses for example lubricin and
CILP2.
In an embodiment, the extended period of time the high cell density Sox9+
collagen2+ chondrocyte precursor population is cultured with the BMP4 agonist is at least 3 weeks, at
least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks,
at least 10 weeks, at least 11 weeks, at least 12 weeks or more to generate a cartilage like tissue that
expresses collagen 2 or hypertrophic chondrocyte cells that express collagen 10.
Described herein is a method of generating chondrocyte like cells comprising:
(a) culturing chondrocyte precursor cells at a high cell density in serum free or serum
containing media;
(b) culturing the high cell density chondrocyte precursor cells with a TGFbeta agonist in
serum free media; and
(c) either
(i) culturing the chondrocyte precursor cells with a TGFbeta agonist for an
extended period of time to produce articular cartilage like chondrocyte cells;
(ii) culturing the chondrocyte precursor cells with a BMP4 agonist for an
extended period of time to produce hypertrophic chondrocyte lineage cells
and/or cartilage like tissue.
In an embodiment, the chondrocyte precursor cells are primary fetal chondrocytes or
passaged fetal chondrocytes.
In an embodiment, the generated cells and/or tissues are administered to a subject.
Also described herein in another embodiment is an isolated population of articular like
non-hypertrophic chondrocyte like cells and/or cartilage like tissue and/or hypertrophic chondrocyte
like cells and/or cartilage like tissue generated according to a method described herein.
A further aspect described herein includes composition comprising the population of
articular like non-hypertrophic chondrocyte like cells and/or cartilage like tissue and/or hypertrophic
chondrocyte like cells and/or cartilage like tissue, and a carrier optionally PEG, hydrogel, bone
scaffolding, bone substitute scaffolding and/or matrigel. In an embodiment, the carrier is
pharmaceutical grade.
In an embodiment, the isolated population is comprised in a composition comprising a
diluent or carrier, optionally a pharmaceutical diluent. In an embodiment, the diluent is culture media,
optionally comprising a cryopreservation agent such as glycerol and/or DMSO, serum and albumin,
40 such as human serum albumin.
[0026] A further aspect described herein includes a cartilage and/or bone tissue product
comprising the cells or composition described herein, and a scaffold.
Another aspect described herein includes method for ameliorating symptoms and/or
treating a subject in need thereof comprising administering cells and/or tissue generated using a
method described herein and/or transplanting a cartilage and/or bone tissue product described herein.
[0028] Also provided in another aspect described herein is use of cells and/or tissue
generated using a method described herein and/or a cartilage and/or bone tissue product comprising
said cells and/or tissue for ameliorating symptoms and/or treating a subject in need thereof.
A further aspect described herein includes a method of generating a paraxial
mesoderm cell population comprising:
(a) culturing a starting population of pluripotent stem cells with a primitive streak inducing
cocktail to induce a primitive streak-like mesoderm cell population expressing CD56
and PDGFR-alpha (e.g. stage 0);
(b) culturing a primitive streak-like mesoderm cell population expressing CD56 and
PDGFR-alpha with a paraxial mesoderm specifying cocktail comprising:
(i) a FGF agonist; and
(ii) a BMP inhibitor, optionally Noggin, LDN-193189, Dorsomorphin; and
(iii) one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor,
optionally DKK1, IWP2, and/or XAV939;
to specify a paraxial mesoderm cell population expressing cell surface CD73, CD105 and PDGFR-
beta.
Methods of isolating cells and screening assays are also described herein.
Other features and advantages of the present disclosure will become apparent from
the following detailed description. It should be understood, however, that the detailed description and
the specific examples while indicating preferred embodiments of the disclosure are given by way of
illustration only, since various changes and modifications within the spirit and scope of the disclosure
will become apparent to those skilled in the art from this detailed description.
In the description in this specification reference may be made to subject matter which
is not within the scope of the appended claims. That subject matter should be readily identifiable by a
person skilled in the art and may assist in putting into practice the invention as defined in the
appended claims.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise, reference to
such external documents is not to be construed as an admission that such documents, or such
sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge
in the art.
Brief description of the drawings
An embodiment of the present disclosure will now be described in relation to the
drawings in which:
Figure 1. Serum-free differentiation of paraxial mesoderm, chondrocyte progenitors,
and cartilage tissues from human pluripotent stem cells (hPSCs). (A) hPSCs are differentiated in 4
stages including the induction of a primitive streak-like mesoderm population (stage 1) using Activin A,
BMP4 and basic (b) FGF from days 1 to 4 of differentiation as embryoid bodies. On day 4 (T4),
mesoderm populations are monitored by the expression of CD56 and PDGFRa on the cell surface by
flow cytometry (B). Day 4 mesoderm cells are specified to a paraxial mesoderm fate in monolayer
culture by treatment of Dorsomorphin, a BMP inhibitor, a TGFbeta inhibitor SB431542, and bFGF,
from days 4 to 6 and bFGF from days 4 to 15 (stage 2). Day 15 paraxial mesoderm cells can generate
chondrocyte progenitors by plating in a high density ‘spot’ termed micromass, or by plating onto
collagen coated membrane filters (not shown) in the presence of TGFB3 for approximately 10 days
(stage 3). Chondrocyte progenitors can be specified to articular chondrocytes or growth plate-like
chondrocytes in a cartilage tissue format during stage 4 of differentiation by extended stimulation with
TGFB3 (articular) or BMP3 (growth plate-like) for example for 12 weeks. Tissues have been kept in
culture for at least 7 months. Efficient induction of a primitive streak-like population from hESCs (C)
and hIPSCs (D,E) was confirmed by the expression of CD56 and PDGFRα by flow cytometry on day
3 of differentiation. hESCs were induced to generate a primitive streak population with the following
cytokines: Activin A (2 ng/ml), BMP4 (3 ng/ml) and basic (b)FGF (5 ng/ml). hiPSCs were induced to
generate a primitive streak-like mesoderm population (Stage 1) using Activin A (3 ng/ml), BMP4 (1
ng/ml), bFGF (5 ng/ml) in the presence (C) or absence (D) of the Wnt pathway agonist CHIR99061 (1
µM) from days 1 to 3 of differentiation as embryoid bodies.
Figure 2. Characterization of paraxial mesoderm derived from hPSCs. Flow
cytometric analysis of day 5 mesoderm treated with no additional factors (0 DM, no FGF), FGF, 4 µM
DM, or 4 µM DM+FGF. Day 5 profiles depict KDR and PDGFRa expression, a double-positive
population (gated) indicates mesoderm that has cardiac potential (20). Treatment with FGF results in
less PDGFRa expression on day 5. (B) Expression of cell surface markers CD73, CD105, and
PDGFR-beta on mesoderm populations on day 15 of differentiation. (C) Wnt inhibition can also
improve the efficiency of CD73 and CD105 expression. Experimental cell treatments during day 4 to
day 6 include the combination of Dorsomorphin, bFGF, TGFbeta inhibitor (SB431542) in the presence
or absence of the wnt pathway inhibitor IWP2. Flow cytometric analyses of CD73 and CD105, on day
40 15 mesoderm populations derived as indicated. (D) Gene expression analyses of day 15 mesoderm
populations derived in indicated factors. Nkx2.5 is a cardiac transcription factor, Meox1 and Nkx3.2
are paraxial mesoderm and somite transcription factors. (E) Micrographs depicting 1 day old
micromasses and 1 week old micromasses derived from day 15 mesoderm populations as indicated.
(F) Flow cytometric analysis of cardiac troponin T (cTnT) expression in 1 week old micromasses
derived from day 15 mesoderms as indicated. (G) 4 week old micromasses derived from DM+FGF-
treated paraxial mesoderm generates cartilage tissues, but mesoderm specified with FGF alone do
not generate cartilage-like tissues (see non-adherent aggregates).
[0037] Figure 3. CD73+CD105+PBeta+ cells contain chondrocyte potential and the potential
to generate cartilage-like tissues in-vitro. (A) Flow cytometric analysis of DM+FGF-treated paraxial
mesoderm on day 12 and day 15. Double-positive (CD73+CD105+ and CD73+PBeta+) populations
were isolated from the double-negative populations by cell sorting and plated in micromass culture.
(B) Micromass cultures after 10 days of culture. (C) Micromass cultures after 2 weeks of culture. (D)
Photographs of cartilage tissues derived from sorted populations after 5 weeks of culture.
Figure 4. TGFB3 and BMP4 specify chondrocytes and cartilage-like tissues with
articular cartilage and growth plate cartilage phenotypes. (A) Micrographs of 5 week old micromasses
derived with TGFB3 or BMP4, 20x magnification. (B) Tissue histology (stained with toluidine blue) of
13 week cartilage tissues derived with TGFB3 or BMP4. Toluidine blue stains cartilage tissues
metachromatically, and these tissue sections are pink/purple in color indicating that cartilage tissue is
present. (C) Flow cytometric analysis of forward and side cell scatter parameters of 3 week and 5
week old micromasses. Side scatter indicates cell granularity and forward cell scatter indicates cell
size. (D) Comparison of hPSC-derived micromass tissues to fetal primary chondrocyte derived
micromass tissues and the developing human fetal femur cartilage. Articular cartilage regions appear
to have smaller cells in size compared to growth plate like regions, which contain cells which appear
enlarged (hypertrophic). Cartilage tissues in micromass as well as in the fetal femur stain uniformly
with the toluidine blue stain (images are pink/purple in color and indicate the presence of cartilage
proteins). The BMP4-treated micromass tissues contain a large number of enlarged cells which is
similar to the bottom panel of the fetal cartilage which represents a growth plate cartilage. TGFB3
treated micromass cultures contain fewer, if any, enlarged chondrocytes, and appear similar to the
upper panel of the fetal cartilage which is the site of articular cartilage. (E) Micrograph using GDF5
instead of BMP4 to generate hypertrophic chondrocytes. (F) Histological analyses of cartilage tissues
derived from hiPSCs stained with Toluidine blue after 12 weeks. (G,H) Immunohistochemical staining
of hESC-derived cartilage tissues for type II Collagen (G, 8 week tissues), and lubricin (H, 12 week
tissues).
Figure 5. Gene expression analyses of chondrocyte specification in the presence of
TGFB3 or BMP4 during stages 3 and 4 of differentiation respectively. General chondrocyte genes
Sox9 (A) and collagen 2 (B), hypertrophic genes collagen 10 (C), Runx2 (D), osterix (E) and alkaline
phosphatase (F), articular cartilage associated genes lubricin (G) and cartilage intermediate layer
40 protein 2 (CILP2) (H), interzone-related (joint progenitor) genes GDF5 (I), ERG (J) and Wnt9a (K).
Expression is copy number relative to TBP (n = 3 to 8 biological replicates) and is compared to
primary fetal chondrocytes (aged 16 to 19 weeks, n = 4), primary healthy adult articular chondrocytes
(n = 2), and growth plate-like chondrocytes isolated from the iliac crest of an adult (n = 1). T15
Mesoderm indicates day 15 hESC-derived paraxial mesoderm (DM+FGF-treated). Error bars indicate
s.e.m.
Figure 6. CD73 is expressed by articular chondrocytes. Flow cytometric analyses of
primary chondrocytes (A) Healthy adult articular chondrocytes and iliac crest GPC-like chondrocytes,
(B) Primary fetal chondrocytes, primary (C) or passaged (passage (P)2, D) fetal chondrocytes after 9
to 10 weeks of micromass culture in the presence of TGFB3 or BMP4, and (E,F) hPSC-derived
chondrocytes after 11 weeks derived in the presence of TGFB3 or BMP4. (G) Time course of CD73
and PDGFR-beta cells surface expression on T12 and T15 paraxial mesoderm populations, and
micromass cultures treated with TGFB3 after 3 days, 10 days, and 2 weeks. (H) Time course of CD73
expression on TGFB3-treated micromasses after 3 days, 7 days, 10 days, and 2 to 5 weeks.
Figure 7. hPSC-derived chondrocytes maintain respective articular or hypertrophic
chondrocyte phenotypes in vivo. Micromass tissues (aged 8-12 weeks) treated with TGFβ3 or BMP4
were dissociated by collagenase treatment and chondrocytes were injected subcutaneously into
immunodeficient mice for 12 weeks. Grafts were harvested and analyzed histologically after 12
weeks. Sections were stained with Toluidine blue (A, C) to indicate the presence of proteoglycans and
von Kossa (B) to identify areas of mineralization. Type II (D) and type X collagen (E) was detected
immunohistochemically. After 12 weeks in vivo, TGFβ3-treated chondrocyte-derived grafts stained
positive for type II collagen (D) and stained metachromatically with toluidine blue (A, C), and no areas
of von Kossa (B) or type X collagen positivity (E) were found. Areas of mineralization (B), von Kossa
positive, black) were identified in grafts derived from BMP4-treated chondrocytes after 12 weeks, but
these areas contained little proteoglycan (A, C) and stained positively for type II (D) and type X
collagen (E), indicating the development of calcified cartilage.
Figure 8. TGFβ1, TGFβ2, and TGFβ3 generated articular chondrocytes from hPSC-
derived paraxial mesoderm. COL2A1, lubricin, and CILP2 gene expression after 12 weeks of
micromass culture in the presence of TGFβ agonists as indicated (10 ng/ml). Values represent copy
number mRNA relative to TBP. Error bars indicate s.e.m.
Figure 9. hPSC-derived articular-like cartilage respond appropriately to the pro-
inflammatory molecule IL1β. (A) The experimental plan is depicted. Articular cartilage tissues were
derived from hPSCs for 10 weeks in the presence of TGFβ3. Cartilage tissues (micromasses) were
treated for two weeks (from week 10-12) with TGFβ3 or IL1β (10 ng/ml), as indicated. Cartilage
tissues were analyzed histologically or dissociated for gene expression analyses. hPSC-derived
articular chondrocytes significantly upregulated the expression of MMP13 (B), MMP2 (C), ADAMTS4
(D) and ADAMTS5 (E) in response to exogenous IL1β. (F, G) Genes encoding extracellular matrix
components, COL2A1 and ACAN, are significantly downregulated in response to IL1β. (H, I)
40 Expression of superficial zone chondrocyte genes PRG4 (lubricin) and CILP2 were downregulated in
presence of IL1β. (J) VEGF was upregulated in the presence of IL1β. Values represent copy number
mRNA relative to TBP (n=7). Error bars indicate s.e.m. (K) Histological analysis of 12-week tissues
after treatments as indicated. Metachromatic toluidine blue staining indicates proteoglycans.
Detailed description of the Disclosure
1. Definitions
[0044] The term “primitive streak-like mesoderm cell population” as used herein means a population
of mesoderm cells expressing Brachyury and the cell surface markers CD56 and PDGFRalpha. For
example, the primitive streak-like mesoderm cell population can comprise at least 50%, at least 60%,
at least 70%, at least 80% or about 90% cells expressing CD56 and PDGFRalpha Cartilage
differentiation has been obtained with the disclosed methods using for example 50%
CD56/PDGFRalpha+ cells.
The term “paraxial mesoderm cell population expressing cell surface CD73, CD105 and/or
PDGFR-beta” as used herein means mesoderm cells expressing CD73, CD105 and/or PDGFR-beta
and the paraxial mesoderm transcription factor Meox1. For example, the paraxial mesoderm cell
population comprises at least 70% cells expressing Meox1, CD73, CD105 and/or PDGFR-beta As
shown in Fig. 2D. Meox1 expression is increased in FGF and Dorsomorphin treated cells compared to
non FGF and Dorsomorphin treated cells.
As used herein, the term "express" refers to the transcription of a polynucleotide or
translation of a polypeptide in a cell, such that levels of the molecule are measurably higher in a cell
that expresses the molecule than they are in a cell that does not express the molecule. Methods to
measure the expression of a molecule are well known to those of ordinary skill in the art, and include
without limitation, Northern blotting, RT-PCR, in situ hybridization, Western blotting, and
immunostaining such as FACS.
The term “expressing” also represented as “+” as used herein means, with respect to a cell
protein level, detectable protein expression compared to a cell that is not expressing the protein, for
example as measured by FACS analysis. Using FACS analysis, a cell is considered positively
expressing the protein on the cell surface if the mean fluorescence of the signal is brighter than a cell
that was not stained with the antibody (unstained control) or cells that were stained with the antibody
but do not express the protein on the cell surface. With respect to a cell population, “expressing” as
used herein means at least 50% of the cells in the cell population express the marker. In an
embodiment, the cells expressing for example cells expressing CD73 or the other markers are sorted
such that for example 70%, 80, 90% or more of the cells are positive and express the marker.
The term “lacking expression” also represented as “-“ as used herein means with respect to
a cell protein level, undetectable protein expression compared to a cell that is expressing the protein,
40 for example as measured by FACS analysis. With respect to a cell population, “lacking expression” as
used herein means less than 25%, less than 20%, less than 15%, less than 10%, less than 5% or less
than 1% of the cells in the cell population express the marker.
The term “culturing” as used herein incubating and/or passaging cells in an adherent,
suspension or 3D culture. As used herein, the term "adherent culture" refers to a cell culture system
whereby cells are cultured on a solid surface, which may in turn be coated with an insoluble substrate
that may in turn be coated with another surface coat of a substrate, such as those listed below, or any
other chemical or biological material that allows the cells to proliferate or be stabilized in culture. The
cells may or may not tightly adhere to the solid surface or to the substrate. The substrate for the
adherent culture may comprise any one or combination of tissue culture treated plastic, polyornithine,
laminin, poly-lysine, purified collagen, gelatin, fibronectin, tenascin, vitronectin, entactin, heparin
sulfate proteoglycans, poly glycolytic acid (PGA), poly lactic acid (PLA), and poly lactic-glycolic acid
(PLGA). In one embodiment, the cells are plated on MATRIGEL®-coated plates. In another
embodiment, the cells are plated on fibronectin-coated plates. Cells can be cultured in filter cultures
and micromass cultures. In an embodiment, cells are plated onto membrane filters, optionally those
that are placed into tissue cultures dishes as part of a transwell system (Millipore, alvatex are two
brands). The substrate could also be a bone scaffold substitute such as CPP (calcium polyphosphate)
or other pharmaceutically available scaffolds available. Micromass culture is comprised of a high
density suspension of cells is permitted to adhere to a small area of the substrate (e.g. 200,000-
500,000 cells adhere to a 0.2-1 cm diameter circular area of the substrate). Any shape or size of
substrate can be used, prepared for example by 3D printing. The term "suspension" as used in the
context of cell culturing is used as it is in the art. Namely, cell culture suspensions are cell culture
environments where the cells do not adhere to a surface. One of skill in the art will be familiar with
suspension culture techniques, including, but not limited to, the use of equipment such as flow hoods,
incubators and/or equipment used to keep the cells in constant motion, e.g., rotator platforms,
shakers, etc, if necessary.
[0051] The term “contacting” or “culturing … with” is intended to include incubating the
component(s) and the cell/tissue together in vitro (e.g., adding the compound to cells in culture) and
the step of “contacting” or “culturing… with” can be conducted in any suitable manner. For example
the cells may be treated in adherent culture, or in suspension culture, or in 3D culture; the
components can be added temporally substantially simultaneously (e.g. together in a cocktail) or
sequentially (e.g. within 1 hour, 1 day or more from an addition of a first component). The cells can
also be contacted with another agent such as a growth factor or other differentiation agent or
environments to stabilize the cells, or to differentiate the cells further and include culturing the cells
under conditions known in the art. Stage 1 for example is typically practiced in suspension culture.
Stag 2 is in an embodiment carried outin suspension. Stage 3and/or4 can for example be carried
40 out in suspension culture for example if the cells are aggregated in a pellet format instead of a
micromass or filter format. Pellet cultures are a cluster of cells at high density that can float in
suspension in a tube. In an embodiment, part of a stage is carried out in suspension or mixed
suspension and adherent, optionally 3D culture. For example, some tissues become non-adherent
over time and are thus in suspension for some of the culture period of stage 4.
The term “high cell density” as used herein means about 200,000 cells - about1,000,000
cells per about 0.2 cm – about 2cm diameter surface area (2D), or with respect to micromass is at
least about 100,000 cells per about 20 microliters of media, or for example upt to about 2,000,000
cells per about 20 microliters of media to allow for cells to adhere to the small surface area permitted
for a micromass ‘spot’. For membrane filters, the area is dependent on the commerically available
membrane that is purchased, for example approximately 400,000 cells- about 2,000,000 cells can be
plated in about 200 microliters – about 500 microliters of media in for example a about 1cm - about
2cm cylinder shaped membrane filter-containing insert to allow cells to adhere. In both mircomass
and membrane filter culture, cells adhere in about a 1-5 cell layer and tissue is permitted to grow
‘thicker ‘after adherence. A similar cell density could be used to seed onto a bone substitute scaffold
such as the CPP.
As used herein, "serum free" refers to the absence of serum in the solutions e.g. medias
used to culture the given cell population. For example, serum free medium or environment can
contain less than 4, 3, 2, or 1% serum. In a preferred embodiment, the serum free composition does
not contain serum, or only contains trace amounts of serum from the isolation of components that are
added to the defined media (e.g. contains 0% added serum).
The term “BMP inhibitor” as used herein means any inhibitor of BMP signaling and includes
for example a type 1 BMP receptor inhibitor, BMP ligands and/or soluble BMP receptors, optionally
selected from dorsomorphin (DM), noggin, Chordin, LDN-193189, soluble BMPR1a, and/or soluble
BMPR1b.
The term “FGF agonist” as used herein means a molecule such as a cytokine, including for
example FGF, or a small molecule, that activates a FGF signalling pathway, e.g binds and activates a
FGF receptor.
[0056] The term “FGF” as used herein refers to any fibroblast growth factor, and optionally bFGF,
FGF2, FGF4, FGF9 and/or optionally FGF 19, 21, 3, 5, 6, 8a, 16-18, 20 and/or 23, for example human
FGF1 (Gene ID: 2246), FGF2 (also known as bFGF; Gene ID: 2247), FGF3 (Gene ID: 2248), FGF4
(Gene ID: 2249), FGF5 (Gene ID: 2250), FGF6 (Gene ID: 2251), FGF7 (Gene ID: 2252), FGF8 (Gene
ID: 2253), FGF9 (Gene ID: 2254) and FGF10 (Gene ID: 2255) optionally including active conjugates
and fragments thereof, including naturally occuring active conjugates and fragments. In certain
embodiments, FGF is bFGF, FGF2, FGF4, and/or FGF9. As used herein, “active conjugates and
fragments of FGF” include conjugates and fragments of a fibroblast growth factor that bind and
activate a FGF receptor and optionally activate FGF signalling.
The term “TGFbeta agonist” or TGFb agonist as used herein any molecule that promotes
40 TGFbeta signaling and includes for example TGFb1, TGFb2 and/or TGFb3.
[0058] The term “TGFbeta inhibitor” as used herein means any molecule that inhibits receptors
ALK4 and ALK7 and/or TGF-βRI, for example SB431542 (Sigma Aldrich) A83-01 (Tocris, 2929), D
4476, GW 788388, LY 364947, RepSox, SB 505124, SB 525334 (Sigma Aldrich), and SD 208.
The term “BMP4 agonist” as used herein means any molecule optionally any BMP or GDF
that activates the receptor for BMP4, including for example GDF5, GDF6, GDF7, BMP4, BMP2,
BMP6, BMP7 and/or, BMP10.
The term “BMP4” (for example Gene ID: 652) as used herein refers to Bone Morphogenetic
Protein 4, for example human BMP4, as well as active conjugates and fragments thereof, optionally
including naturally occuring active conjugates and fragments, that can for example activate BMP4
receptor signlaing.
[0061] The term “nodal agonist” as used herein means any molecule that activates nodal signal
transduction such as “nodal” (for example human nodal such as Gene ID: 4338) or “activin” in a
hepatocyte lineage cell.
The term “activin” or “ActA” as used herein refers to “Activin A” ( for example Gene ID:
3624), for example human activin, as well as active conjugates and fragments thereof, optionally
including naturally occuring active conjugates and fragments, that can for example activate nodal
signal transduction as well as active conjugates and fragments thereof, including naturally occuring
active conjugates and fragments.
The term “a wnt agonist” as used herein means any molecule that activates wnt/beta-catenin
receptor signaling in a chondrocyte lineage cell and incldues for example Wnt3a and as well as GSK3
selective inhibitors such as CHIR99021 (Stemolecule™ CHIR99021 Stemgent), 6-BromoIndirubin-3’-
Oxime (BIO) (Cayman Chemical (cat:13123)), or Stemolecule™ BIO from Stemgent (cat:04003).
CHIR99021 is a selective inhibitor of GSK3. The GSK3 selective inhibitors contemplated are for
example selective inhibitors for GSK-3α/β in the Wnt signaling pathway.
The term “Wnt3a” as used herein refers to wingless-type MMTV integration site family,
member 3A factor (e.g. Gene ID: 89780), for example human Wnt3a, as well as active conjugates and
fragments thereof, including naturally occuring active conjugates and fragments.
The term “Wnt antagonist” or “wnt inhibitor” as used herein means any molecule that inhibits
wnt/beta cantenin receptor signaling in a chondrocyte lineage cell, including for example IWP2 (N-(6-
Methylbenzothiazolyl)[(3,4,6,7-tetrahydrooxophenylthieno[3,2-d]pyrimidinyl)thio]-
acetamide; Sigma); Dickkopf-related protein 1 (DKK1; R & D Systems), and/or XAV939 (3,5,7,8-
Tetrahydro[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidinone; Sigma).
The term “agonist” as used herein means an activator, for example, of a pathway or
signaling molecule. An agonist of a molecule can retain substantially the same, or a subset, of the
biological activities of the molecule (e.g. nodal). For example, a nodal agonist means a molecule that
40 selectively activates nodal signaling.
[0067] The term “inhibitor” as used herein means a selective inhibitor, for example of a pathway or
signaling molecule. An inhibitor or antagonist of a molecule (e.g. BMP4 inhibitor) can inhibit one or
more of the activities of the naturally occurring form of the molecule. For example, a BMP4 inhibitor is
a molecule that selectively inhibits BMP4 signaling.
The term “selective inhibitor” as used herein means the inhibitor inhibits the selective entity
or pathway at least 1.5X, 2X, 3X, 4X or 10X more efficiently than a related molecule.
The term “specifying” as used herein means a process of committing a cell toward a specific
cell fate, prior to which the cell type is not yet determined and any bias the cell has toward a certain
fate can be reversed or transformed to another fate. Specification induces a state where the cell’s fate
cannot be changed under typical conditions. Specification is a first step of differentiation.
[0070] The term "stem cell" as used herein, refers to an undifferentiated cell which is capable of
proliferation, self-renewal and giving rise to more progenitor or precursor cells having the ability to
generate a large number of mother cells that can in turn give rise to differentiated, or differentiable,
daughter cells. The daughter cells can for example be induced to proliferate and produce progeny
cells that subsequently differentiate into one or more mature cell types, while also retaining one or
more cells with parental developmental potential. The term “stem cell” includes embryonic stem cell
and pluripotent stem cell.
The term "embryonic stem cell" is used to refer to the pluripotent stem cells of the inner cell
mass of the embryonic blastocyst (see, for example, U.S. Pat. Nos. 5,843,780, 6,200,806). Such cells
can also be obtained from the inner cell mass of blastocysts derived from somatic cell nuclear transfer
(see, for example, U.S. Pat. Nos. 5,945,577, 5,994,619, 6,235,970).
The term "pluripotent stem cell" as used herein refers to a cell with the capacity, under
different conditions, to differentiate to more than one differentiated cell type, and for example the
capacity to differentiate to cell types characteristic of the three germ cell layers. Pluripotent cells are
characterized by their ability to differentiate to more than one cell type using, for example, a nude
mouse teratoma formation assay. Pluripotency is also evidenced by the expression of embryonic stem
(ES) cell markers. Pluripotent stem cells include induced pluripotent stem cells (iPSC) and embryonic
stem cells. In an embodiment, the pluripotent stem cell is derived from a somatic cell. In an
embodiment, the pluripotent stem cell is derived from a human somatic cell.
As used herein, the terms "iPSC" and "induced pluripotent stem cell" are used
interchangeably and refers to a pluripotent stem cell artificially derived (e.g., induced or by complete
reversal) from a non-pluripotent cell, typically an adult somatic cell, for example, by inducing
expression of one or more genes including POU4F1/OCT4 (Gene ID; 5460) in combination with, but
not restricted to, SOX2 (Gene ID; 6657), KLF4 (Gene ID; 9314), cMYC (Gene ID; 4609), NANOG
(Gene ID; 79923), LIN28/ LIN28A (Gene ID; 79727)). The expression can be induced for example by
40 forced gene expression or using small molecules, small RNAs, non-integrating gene expression
vectors, or proteins.
[0074] The term “chondrocyte like cells” as used herein means chondrocyte cells and cells that are
cytochemically similar and express chondrocyte markers, including for example Sox9 and Collagen 2,
and behave as chondrocyte cells. The chondrocyte cells can be articular cartilage like chondrocytes
or precursors or chondrocytes that are capable of hypertrophy (optionally referred to as GPC like
cells) or precursors thereof.
[0075] The term “cartilage like tissue” as used herein means cartilage tissue and tissue that is
histologically similar and expresses cartilage markers, for example collagen 2 and aggrecan, and
behaves as cartilage, including articular cartilage tissue and/or growth plate cartilage like tissue.
The term “articular chondrocyte like cells and/or cartilage tissue” as used herein means a
population, optionally enriched or mixed, comprising articular chondrocyte cells and/or articular
chondrocyte like cells including for example, cartilage like tissue comprising articular chondrocyte like
cells.
The term “hypertrophic chondrocyte like cells and/or cartilage tissue” or “GPC like cells
and/or cartilage tissue” as used herein means a population, optionally enriched or mixed, comprising
hypertrophic chondrocyte cells and/or hypertrophic chondrocyte like cells (e.g. iliac crest
chondrocytes) including for example, cartilage like tissue comprising hypertrophic chondrocyte like
cells.
The term “articular cartilage like tissue” or “cartilage containing non hypertrophic
chondrocyte-like cells” is histologically similar and expresses articular cartilage markers such as
lubricin and/or CILP2 and behaves as articular cartilage. For example, articular cartilage is
maintained as stable cartilage in vivo.
The tem “growth plate cartilage like tissue” as used herein means cartilage tissue that is
histologically similar and expresses cartilage markers that are found in growth plate cartilage tissue
including collagen X, RUNX2, SP7 and/or alkaline phosphates and behaves like growth plate cartilage
For example, growth plate cartilage functions in vivo to provide a scaffold onto which new bone will
form.
The term "isolated population" with respect to an isolated population of cells as used herein
refers to a population of cells that has been removed and separated from a mixed or heterogeneous
population of cells. In some embodiments, an isolated population is a substantially pure population of
cells as compared to the heterogeneous population from which the cells were isolated or enriched
from.
The term "substantially pure", with respect to a particular cell population, refers to a
population of cells that is at least about 65%, preferably at least about 75%, at least about 85%, more
preferably at least about 90%, and most preferably at least about 95% pure, with respect to the cells
making up a total cell population.
[0082] The terms "enriching" or "enriched" are used interchangeably herein and mean that the yield
(fraction) of cells of one type is increased by at least about 10%, at least about 20%, at least about
%, at least about 40%, at least about 50% or at least about 60% over the fraction of cells of that
type in the starting culture or preparation. Enriching and partially purifying can be used
interchangeably.
[0083] The population of cells can be enriched using different methods such as methods based on
markers such as cell surface markers (e.g. FACS sorting etc).
The term "subject" as used herein includes all members of the animal kingdom including
mammals such as and including a primate such as human, monkey or ape, a dog, cat, cow, horse,
goat, pig, rabbit, sheep or a rodent such as a rat, or mouse, and suitably refers to a human.
[0085] The terms "treat", "treating", "treatment", etc., as applied to an isolated cell, include
subjecting the cell to any kind of process or condition or performing any kind of manipulation or
procedure on the cell. As applied to a subject, the terms refer to providing medical or surgical
attention, care, or management to a subject.
The term “treatment” as used herein as applied to a subject, refers to an approach aimed at
obtaining beneficial or desired results, including clinical results and includes medical procedures and
applications including for example pharmaceutical interventions, surgery, radiotherapy and
naturopathic interventions as well as test treatments for treating joint/bone disorders. Beneficial or
desired clinical results can include, but are not limited to, alleviation or amelioration of one or more
symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of
disease, preventing spread of disease, delay or slowing of disease progression, amelioration or
palliation of the disease state, and remission (whether partial or total), whether detectable or
undetectable.
As used herein, the terms "administering", "implanting" and "transplanting" are used
interchangeably in the context of delivering cells tissues and/or products described herein into a
subject, by a method or route which results in at least partial localization of the introduced cells at a
desired site. The cells can be implanted directly to a joint, or alternatively be administered by any
appropriate route which results in delivery to a desired location in the subject where at least a portion
of the implanted cells or components of the cells remain viable.
In understanding the scope of the present disclosure, the term "comprising" and its
derivatives, as used herein, are intended to be open ended terms that specify the presence of the
stated features, elements, components, groups, integers, and/or steps, but do not exclude the
presence of other unstated features, elements, components, groups, integers and/or steps. The
foregoing also applies to words having similar meanings such as the terms, "including", "having" and
their derivatives. Finally, terms of degree such as "substantially", "about" and "approximately" as used
40 herein mean a reasonable amount of deviation of the modified term such that the end result is not
significantly changed. These terms of degree should be construed as including a deviation of at least
±5% of the modified term if this deviation would not negate the meaning of the word it modifies.
In understanding the scope of the present disclosure, the term “consisting” and its
derivatives, as used herein, are intended to be close ended terms that specify the presence of stated
features, elements, components, groups, integers, and/or steps, and also exclude the presence of
other unstated features, elements, components, groups, integers and/or steps.
The recitation of numerical ranges by endpoints herein includes all numbers and fractions
subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be
understood that all numbers and fractions thereof are presumed to be modified by the term "about."
Further, it is to be understood that "a," "an," and "the" include plural referents unless the content
clearly dictates otherwise. The term “about” means plus or minus 0.1 to 50%, 5-50%, or 10-40%,
preferably 10-20%, more preferably 10% or 15%, of the number to which reference is being made.
Further, the definitions and embodiments described in particular sections are intended to be
applicable to other embodiments herein described for which they are suitable as would be understood
by a person skilled in the art. For example, in the following passages, different aspects of the
invention are defined in more detail. Each aspect so defined may be combined with any other aspect
or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being
preferred or advantageous may be combined with any other feature or features indicated as being
preferred or advantageous.
2. Methods and products
[0092] Described here are methods of producing paraxial/chondrogenic mesoderm cells
from human pluripotent stem cells (PSCs); of generating articular cartilage-like tissue in-vitro that
expresses the articular cartilage marker lubricin and histologically cannot be distinguished for example
from human cartilage tissue of the knee joint; as well as methods of making a cartilage-like tissue with
growth plate-like properties, which is the second type of cartilage found in humans, and is the
cartilage that is responsible for the growth of long bones due to its propensity to undergo hypertrophy
and express collagen 10. Chondrocyte cells prepared using methods described herein are further
demonstrated to be stable and maintain their articular cartilage like or growth plate cartilage like
properties after transplant. In addition, CD73 cell surface marker was found to be expressed by
articular chondrocytes.
[0093] It is demonstrated herein that CD73 is expressed by primary adult and fetal healthy
chondrocytes as well as hESC-derived articular-like chondrocytes but is not expressed on growth
plate-like chondrocytes derived from hESCs.
The methods described use, in an embodiment, serum free methods to generate
paraxial/chondrogenic mesoderm (CD73+CD105+PDGFRbeta+), as well as organized cartilage-like
40 tissue that resembles human cartilage for example of the knee. Serum free methods disclosed herein
are useful for cell and tissue based engineering strategies and may be used for example for articular
cartilage replacement. These cells are also useful for identifying molecules that may be involved in
degradation of cartilage in patients with osteoarthritis, drug discovery applications which identify
molecules that can permit expansion of these chondrocytes in-vitro for potential application to
autologous chondrocyte transplantation surgeries, or drugs that may attentuate osteoarthritis. Further,
access to both pluripotent stem cell-derived articular and growth plate-like cartilage tissues will allow
for the development of cell and tissue based therapies for treatment of osteoarthritis as well as other
joint and bone disorders.
It is demonstrated herein for example that, chondrocyte specification can be
accomplished in a high-density culture of the paraxial mesoderm population in serum free media
containing TGFb3, TGFb2 or TGFb1 for a brief period (e.g. 10 days). Continued or extended TGFb
agonist stimulation generates cartilage tissue with articular cartilage characteristics (histology and
gene expression), while stimulation with BMP4 induces a growth plate-like cartilage tissue containing
hypertrophic chondrocytes.
Extended culture has been performed, for example for over a 12 week, or longer
optionally 14 week period, during which maturation of tissue to lubricin+ or collagen 10+ cartilage
tissue was demonstrated.
Using the methods described herein co-culture-with other cells is not required, nor is
conditioned media or a scaffold, although these can be used in some embodiments.
CD73 expression, a cell surface marker, is demonstrated to mark healthy primary
adult and fetal articular chondrocytes but is not expressed in adult growth plate chondrocytes of the
iliac crest. Similar to primary healthy articular chondrocytes, hESC-derived articular-like chondrocytes
(TGFB3-treated) express CD73. Conversely, hESC-derived growth plate-like chondrocytes (BMP4-
treated) express significantly less CD73. This marker can be used to distinguish these two
chondrocyte sub-populations, where CD73 is expressed by both primary and hESC-derived articular
chondrocytes but is not expressed (substantially) on growth plate like chondrocytes.
[0099] Accordingly, an aspect disclosed includes a method for generating chondrocytes
and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue
and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising:
(a) culturing a primitive streak-like mesoderm cell population, optionally a CD56+ and/or
PDGFRalpha+ primitive streak-like mesoderm population, with a paraxial mesoderm
specifying cocktail comprising:
(i) a FGF agonist;
(ii) a BMP inhibitor, optionally Noggin, LDN-193189, Dorsomorphin; and
(iii) optionally one or more of a TGFbeta inhibitor, optionally SB431542; and a
wnt inhibitor;
40 to specify a paraxial mesoderm population expressing cell surface CD73, CD105
and/or PDGFR-beta;
(b) generating a chondrocyte precursor population comprising:
(i) culturing the paraxial mesoderm population expressing CD73, CD105 and/or
PDGFR-beta at a high cell density in a serum free or serum containing
media;
(ii) culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial
mesoderm population with a TGFbeta agonist in serum free media to
produce a high cell density Sox9+, collagen 2+ chondrocyte precursor
population; and
(c) either:
(i) culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor
population with the TGFbeta agonist for an extended period of time to
produce articular like non-hypertrophic chondrocyte cells and/or cartilage like
tissue; or
(ii) culturing the high cell density Sox9+ collagen2+ chondrocyte precursor
population with a BMP4 agonist for an extended period of time to produce
hypertrophic chondrocyte like cells and/or cartilage like tissue.
In an embodiment, the TGFbeta agonist is selected from TGFb1, TGFb2, TGFb3
and/or combinations thereof. In an embodiment, the TGFbeta agonist is TGFb1.
In methods described herein, the agonist, inhibitor or component can be added on
day 1 of a time period for a specific time period or added repeatedly during a time period for example
with media changes. For example, FGF is required for example at day 4 and is added with culture
media replacement until day 15.
In an embodiment, the media used in one or more or all steps is serum free. It is
demonstrated that a wnt antagonist (e.g. a wnt pathway inhibitor) can increase CD73 and CD105
expression when inducing a primitive streak mesoderm population derived from induced PSCs.
[00103] In an embodiment the method is for generating articular like non-hypertrophic
chondrocyte like cells and/or cartilage like tissue, and step c) comprises culturing the high cell density
Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta agonist for an extended
period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like
tissue.
[00104] In another embodiment, the BMP4 agonist is BMP4.
In another embodiment the method is for generating hypertrophic chondrocyte like
cells and/or cartilage like tissue, and step c) comprises culturing the high cell density Sox9+
collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to
produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.
[00106] In an embodiment, the TGFbeta inhibitor is selected from SB431542 A 83-01, D
4476, GW 788388, LY 364947, RepSox, SB 431542, SB 505124, SB 525334, SD 208 (e.g. any
inhibitor of receptors ALK4 and ALK7 and/or TGF-βRI).
The primitive streak like mesoderm that is contacted with mesoderm specifying
cocktail is for example CD56+ and PDGFRalpha+ but does not express cardiomyocyte specific
precursor differentiation markers.
In an embodiment, of the mesoderm specifying cocktail comprises a TGFbeta
inhibitor, optionally SB431524.
In an embodiment, the primitive streak-like mesoderm cell population is cultured with
the TGFbeta inhibitor for at least 2 days (optionally T3-5), 3 days or 4 days.
[00110] In an embodiment, the mesoderm specifying cocktail further comprises a Wnt
inhibitor, optionally DKK1, IWP2, or XAV939. In an embodiment, a Wnt inhibitor is added if for
example the percentage of cells expressing CD73 and CD105 or PDGFRbeta is less than 70%, less
than 60%, 50%, less than 40%, less than 30% or less than 20%.
The percentage of cells expressing CD73 and CD105 or PDGFRbeta can increase if
a Wnt antagonist is used for example for about two days during stage 2 of differentiation. In an
embodiment, the mesoderm specifying cocktail comprises a wnt inhibitor, optionally for 2 days, 3 days
or 4 days.
In an embodiment, the starting primitive streak like mesoderm population is induced
by about day 4 (e.g. KDR+/PDGFRalpha+ cells appear for example at day 5), which for example
induces the CD73, CD105 and PDGFR-beta markers to be upregulated in response to BMP inhibition
and FGF during the paraxial mesoderm specification phase.
In an embodiment, the paraxial mesoderm population is comprised in embryoid
bodies, monolayer culture and/or a combination thereof.
The paraxial mesoderm population can be isolated from any culture, including from
an inefficient differentiation, using cell sorting methods based on the expression of the cell surface
markers, including for example CD73 and CD105 and/or PDGFR-beta. For example, by enriching for
CD73, CD105 and PDGFRbeta cells. The paraxial mesoderm population can also be produced from
induced pluripotent stem cells (iPSCs) obtained from a subject.
Accordingly, a further aspect described herein includes a method for generating
chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or
cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method
comprising:
(a) culturing a starting population of pluripotent stem cells with a primitive streak inducing
cocktail to induce a primitive streak-like mesoderm population expressing CD56 and
PDGFR-alpha;
(b) culturing a primitive streak-like mesoderm population with a paraxial mesoderm
specifying cocktail comprising:
(i) a FGF agonist;
(ii) a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and
(iii) optionally one or more of a TGFbeta inhibitor, optionally SB431524;
and a wnt inhibitor;
to specify a paraxial mesoderm population expressing cell surface CD73, CD105
and/or PDGFR-beta;
(c) generating a chondrocyte precursor population comprising:
(i) culturing the paraxial mesoderm population expressing cell surface CD73,
CD105 and/or PDGFR-beta at a high cell density, optionally in serum free or
serum containing media;
(ii) culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial
mesoderm population with a TGFbeta agonist in serum free media to
produce a high cell density Sox9+, collagen 2+ chondrocyte precursor
population; and
(d) either
(i) culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor
population with a TGFbeta agonist for an extended period of time to produce
an articular like non-hypertrophic chondrocyte cell and/or cartilage like tissue;
(ii) culturing the high cell density Sox9+ collagen2+ chondrocyte precursor
population with a BMP4 agonist for an extended period of time to produce a
hypertrophic chondrocyte like cell and/or cartilage like tissue.
In an embodiment, the method is for generating articular like non-hypertrophic
chondrocyte like cells and/or cartilage like tissue and step d) comprises culturing the high cell density
Sox9+, collagen 2+ chondrocyte precursor population with a TGFbeta agonist, optionally TGFbeta1, 2
and/or 3, for an extended period of time to produce an articular like non-hypertrophic chondrocyte like
cell and/or cartilage like tissue. TGFbeta agonist used in different steps can be the same or different.
In an embodiment, the TGFbeta agonist used to generate a chondrocyte precursor population is the
same TGFbeta agonist used for an extended period of time to produce an articular like non-
hypertrophic chondrocyte cell and/or cartilage like tissue. In another embodiment, the TGFbeta
40 agonist used to generate a chondrocyte precursor population is a different TGFbeta agonist than that
used for an extended period of time to produce an articular like non-hypertrophic chondrocyte cell
and/or cartilage like tissue.
[00117] In another embodiment, the method is for generating hypertrophic chondrocyte like
cells and/or cartilage like tissue, and comprises culturing the high cell density Sox9+ collagen2+
chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce
hypertrophic chondrocyte like cells and/or cartilage like tissue.
In an embodiment, the primitive streak inducing cocktail comprises a nodal agonist,
such as activin A, a BMP4 agonist, a FGF agonist and a wnt agonist.
According to the methods disclosed herein there are typically up to 4 “stages” for
generating chondrocytes and/or articular like cartilage and hypertrophic cartilage, depending on the
stage of the starting population, and include 1. Primitive streak induction; 2. Paraxial mesoderm
specification; 3. Generation of chondrocyte like cells and 4. Generation of cartilage like tissue.
Depending on the starting population, the method can also include a stage 0 which comprises
generation of induced pluripotent stem cells from a somatic cell, generating aggregations of PSCs
either by making embryoid bodies from hPSCs in culture or by generating a single cell suspension
from hPSCs in culture in the presence or absence of self-renewing culture media,
The methods described herein are in an embodiment for generating chondrodcytes
and cartilage tissues from human ESC and tissues. An embodiment comprising these stages is
described in further detail below.
Stage 1 – primitive streak induction
Human primitive streak mesoderm is induced by contacting the pluripotent cells with
primitive streak inducing cocktail for example with activin, BMP4 and basic FGF, for example on
and/or between days 1 and 4 of differentiation In some embodiments, the contacting is during days 1-
3 for example if the CD56+/PDGFRa+ population is generated sooner. In cell lines and starting
populations where endogenous Wnt signaling is absent or low Adding a Wnt agonist can improve the
efficiency of primitive streak formation from PSCs, and blocking Wnt signaling with an antagonist
inhibit primitive streak formation. Endogenous Wnt signaling, is for example sufficient in cell lines
described in the Examples (e.g. HES2). It was found using an iPSC line that a Wnt agonist improved
development of a CD56+PDGFRa+ primitive streak-like population when added from day 1 to day 3.
In an embodiment, the wnt agonist is Wnt3a or a GSK-3 selective inhibitor such as
CHIR-99021 (Stemolecule™ CHIR99021 Stemgent), 6-BromoIndirubin-3’-Oxime (BIO) (Cayman
Chemical (cat:13123)), or Stemolecule™ BIO from Stemgent (cat:04003).
Brachyury expression is also induced during this time, as monitored by gene
expression on approximately day 2-3, and the expression of cell surface markers PDGFRa and CD56
by day 4. In human PSCs, PS-like mesoderm induction relies on activin and wnt signaling (see for
example, 19 20), and is monitored by Brachyury and PDGFRa expression. CD56 can for example be
40 used to monitor for example human primitive streak cell formation.
Stage 2 – paraxial mesoderm
The next stage is the generation of paraxial mesoderm, characterized by the
expression of transcription factors Meox1 and Nkx3.2. The primitive streak (PS)-like cells can for
example be specified to a paraxial fate in monolayer culture, and during this stage (e.g. day 4-6),
BMP signaling can be inhibited using a small molecule such as Dorsomorphin, and TGFb signaling
can be inhibited using a small molecule such as SB431542. Human paraxial mesoderm requires the
addition of FGF (such as bFGF) and it is added to culture media for example, between days 4 and 15
of monolayer culture. A wnt antagonist is also added in some embodiments. The emergence of
human paraxial mesoderm is marked by the expression of cell surface markers including CD73,
CD105, and PDGFRbeta.
[00125] Human paraxial mesoderm can be specified with the BMP inhibitor Dorsomorphin
(e.g. days 4-6) and bFGF during for example a monolayer culture between days 4 and 15 of
differentiation. Day 15 human paraxial mesoderm is characterized by the expression of cell surface
markers CD73, CD105, PDGFRbeta and Meox1 and Nkx3.2 gene expression on day 15. Expression
of these markers begins for example at day 12 and is maximal for example around day 15.
Stage 3 – generation of chondrocytes and Stage 4- generation of tissues
Paraxial mesoderm for example from day 15, can be plated directly into a high cell
density cartilage tissue formation assay such as A micromass or filter culture. Chondrogenesis is
induced in one embodiment with TGFb agonist, for example by culturing with TGFb3 for about 10
days to about 2 weeks, and is characterized by the expression of Sox9 and Collagen 2. A switch to
BMP4 agonist such as BMP4 or GDF containing media induces a hypertrophic chondrocyte
phenotype. Extended TGFb agonist, optionally with TGFb1 or TGFb3, treatment induces an articular
chondrocyte like phenotype in hESC-derived chondrocytes and cartilage tissues, and, GDF5 also
induces a hypertrophic phenotype.
Chondrocytes from human paraxial mesoderm are generated by the plating of day 15
CD73+/CD105+ or CD73+/PDGFRbeta+ cells at a high cell density directly in micromass or filter
cultures in serum free media containing a TGF agonist such as TGFb1 or TGFb3. Cartilage tissues
are generated during this high cell density culture phase by the extended treatment with TGFb agonist
or BMP4 agonist.
Any human embryonic stem cell population can be used as the starting population
including induced pluripotent stem cell populations. In an embodiment, the starting population is a
human embryonic stem cell population (hESC) or an induced pluripotent stem cell population (iPSCs),
optionally primary hESC and/or primary iPSC. Many human ESC lines are commercially available and
listed for example on the NIH HESC registry. In an embodiment, the human ESC population is a cell
line optionally selected from a HES2, H1, H9, or any NIH ESC Registry available hESC cell line; or
40 any human iPS cell line, such as any commercially available iPS cell lines for example as available
from System Biosciences.
[00129] In an embodiment, the starting population is aggregated into embryoid bodies. In
another embodiment, the starting population is cultured in a monolayer.
In an embodiment, the starting population is contacted with the primitive streak
inducing cocktail for about 1 to about 5 days and prior to cardiomyocyte specification. In an
embodiment, the primitive streak inducing cocktail comprises an activin agonist, optionally activin A or
nodal, a BMP4 agonist, optionally BMP4, BMP2, BMP6, BMP7 and/or, BMP10, and a FGF agonist,
optionally bFGF, FGF2, FGF4, FGF9 and/or optionally FGF 19, 21, 3, 5, 6, 8a, 16-18, 20 and/or 23. In
an embodiment, the primitive streak inducing cocktail further comprises a wnt agonist, optionally
selected from Wnt3a and a GSK3b inhibitor such as such as CHIR-99021 (Stemolecule™ CHIR99021
Stemgent), 6-BromoIndirubin-3’-Oxime (BIO) (Cayman Chemical (cat:13123)), and/or Stemolecule™
BIO from Stemgent (cat:04003).
The primitive streak-like mesoderm population expresses both CD56 and
PDGFRalpha, as measured for example by flow cytometry (Fig. 1B). In some cell lines, the induction
takes from T1 (day 1) to T4 (as in the case of the HES2 hESC line used in the Examples). In other cell
lines, such as iPSCs for example, this induction may only require two days (from T1-T3). The
appearance of cell surface markers such as CD56 and PDGFRalpha indicates that stage 1 is
complete and stage 2 can begin.
hiPSCs were differentiated with the following modifications of the protocol shown in
Figure 1A; the Wnt pathway agonist CHIR99061 (1 micromolar) was added to the stage 1 cultures
and stage 1 was shortened from 3 to 2 days. The paraxial mesoderm fate was specified in the
monolayer cultures by treatment with Dorsomorphin (DM) and SB431542 from day 3 to day 5, and
FGF from day 3 to day 14 (Stage 2).
In an embodiment, the iPSCs receive a 3 day induction, and in another embodiment,
an iPSC population receives a two day induction. In an embodiment an hESC population receives a 2
day induction and in another embodiment, the hESC population receives a 3 day induction.
[00134] Stage 2 can be considered two steps, which results in the generation of a population
marked by the expression of CD73, CD105, and/or PDGFR-beta. The cells can be plated in a
monolayer culture in the presence of a BMP inhibitor (e.g. such as Dorsomorphin) and a FGF agonist
such as basic FGF. Dorsomorphin is effective in inhibiting cardiomyocyte specification, for example,
between the window of day 4 to day 6 (T4-T6), and treatment with Dorsomorphin can be limited to this
two day period. FGF agonist, optionally basic FGF, is required for example, for the duration of the
monolayer culture to specify the mesoderm population to a paraxial mesoderm fate.
Accordingly, in an embodiment, the paraxial mesoderm is specified in a monolayer
culture.
In another embodiment, the BMP inhibitor is a type 1 BMP receptor inhibitor and/or
40 soluble BMP receptors, optionally selected from dorsomorphin (DM), noggin, Chordin, LDN-193189,
soluble BMPR1a, and/or soluble BMPR1b.
[00137] In another embodiment, the primitive streak-like mesoderm population is contacted
with the BMP inhibitor for about 1, 2, 3 or 4 days to inhibit cardiomyocyte specification.
In an embodiment, the FGF agonist for specifying the primitive streak-like mesoderm
population and/or the paraxial mesoderm population is selected from FGF2, bFGF, FGF4 and/or
FGF9.
[00139] As mentioned, the emergence of this paraxial mesoderm can be monitored by
detecting the expression of CD73, CD105 and/or PDGFR-beta on the cell surface (observed by flow
cytometry for example as shown in Fig. 2B, 3A). When a population of mesoderm that expresses
these 3 markers emerges (by day 15/T15), this stage ends. Fig. 3A shows the upregulation of these
markers between T12 and T15. These markers are not expressed on a significant portion of cells
between T4 and T10. Over the course of monolayer differentiation (e.g. T4-T15) an upregulation of
Meox1 and Nkx3.2, two transcription factors expressed in paraxial mesoderm and somites are
detected. Expression of these markers in cultures for example by day 15 indicates that paraxial
mesoderm has been generated.
In an embodiment, the primitive streak-like mesoderm population is contacted with
the FGF agonist for at least 5 days, 6 days, 7 days, 8 days, 9 days, 10, days, 11 days, 12 days or
more (for example from T3-T14) to increase the proportion of cells expressing CD73 and/or CD105
for example, by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or 65% compared to FGF
agonist untreated cells.
In an embodiment, the paraxial mesoderm population also expresses transcription
factors Meox1 and Nkx3.2 and is negative for Nkx2.5.
The paraxial mesoderm population can be plated in any high cell density format,
including for example in a micromass culture, pellet culture or filter culture. For example to generate
micromass tissues typically between about 200,000 to about 500,000 cells are plated in one 20
microliter ‘spot’ to start the tissue formation. Any more cells and they will not adhere due to lack of
area available in the spot/tissue culture plastic area, less cells and the ‘spot’ will not be confluent with
cells. As another example, in membrane filter cultures the minimum plating is about 500,000 cells,
and the maximum is about 2 million cells per 12mm diameter filter.
In an embodiment, the paraxial mesoderm population is plated at a cell density
between 10 million cells/ml and 50 million cells/ml, optionally at least 10 million cells per 1 ml, 20
million cells/ml, 30 million cells/ml, 40 million cells/ml or 50 million cells/ml for example in a micromass
culture. In an embodiment, between about 500,000 and 2 million cells, optionally about 500,000,
about 750,000, about 1 million, about 1.25 million, about 1.5 million, about 1.75 million, about 2 million
cells are plated in a 12mm diameter membrane filter culture.
In certain embodiments, serum free methods are used for example to generate
40 CD73+CD105+PDGFRBeta+ paraxial mesoderm from a primitive streak-like mesoderm population
using for example bFGF and BMP inhibition.
[00145] In an embodiment, optionally during stages 3 and/or 4 the media is serum free and
comprises a base media optionally high glucose DMEM + dexamethasone, ascorbic acid, insulin,
transferrin, selenium, and proline. An example of a base media is provided for example in reference
As used herein, a base media refers to a mixture of salts that provide cells with water
and certain bulk inorganic ions essential for normal cell metabolism, maintain intra- and extra-cellular
osmotic balance, provide a carbohydrate as an energy source, and provide a buffering system to
maintain the medium within the physiological pH range. Examples of base medias include, but are not
limited to, Dulbecco's Modified Eagle's Medium (DMEM), Minimal Essential Medium (MEM), Basal
Medium Eagle (BME), RPM1 1640, Ham's F-10, Ham's F-12, alpha-Minimal Essential Medium
(aMEM), Glasgow's Minimal Essential Medium (O-MEM), and Iscove's Modified Dulbecco's
Medium(IMDM), Stem Pro and mixtures thereof. In one particular embodiment, the basal salt nutrient
solution is an approximately 50:50 mixture of DMEM and Ham's F12. In an embodiment, the base
media is high glucose DMEM .
In another embodiment, the media comprises a base media comprising insulin,
transferrin and optionally selenium in combination with DMEM, Stem Pro®, Mesofate (Stemgent),
RMPI 1640 or IMDM.
It is contemplated that the media and/or compositions can further comprise trace
elements. Trace elements can be purchased commercially, for example, from Mediatech. Non-limiting
examples of trace elements include but are not limited to compounds comprising, aluminum, chlorine,
sulfate, iron, cadmium, cobalt, chromium, germanium, sodium, potassium, calcium, phosphate and
magnesium. Specific example of compounds containing trace elements include but are not limited to,
AlCl , AgNO , Ba(C H O ) , CdCl , CdSO , CoCl , CrCl , Cr (SO ) , CuSO , ferric citrate, GeO , Kl,
3 3 2 3 2 2 2 4 2 3 2 4 3 4 2
KBr, LI, molybdic acid, MnSO , MnCl , NaF, Na SiO , NaVO , NH VO , (NH ) Mo O , NiSO , RbCl,
4 2 2 3 3 4 3 4 6 7 24 4
selenium, Na2SeO3, H2SeO3, seleniteNa, selenomethionone, SnCl2, ZnSO4, ZrOCl2, and mixtures and
salts thereof.
It is contemplated that amino acids can be added to the defined media. Non-limiting
examples of such amino acids are Glycine, L-Alanine, L-Alanyl-L-Glutamine, L-Glutamine/Glutamax,
L-Arginine hydrochloride, L-Asparagine, L-Aspartic acid, L-Cysteine, L-Glutamic Acid, L-Histidine, L-
Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Proline, L-
Hydroxyproline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine and L-Valine. In certain
embodiments, the amino acid is L-Isoleucine, L-Phenylalanine, L-Proline, L-Hydroxyproline, L-Valine,
and mixtures thereof.
It is also contemplated that the base media can comprise ascorbic acid.
In addition, the compositions and methods may also comprise other components
40 such as albumin, transferrin, L-glutamine, lipids, antibiotics, betaMercaptoethanol, vitamins, minerals,
ATP and similar components may be present. In another specific embodiment, the compositions and
methods comprise vitamin D and ATP.
In an embodiment, the high cell density spot is maintained for about 0 to 4 days, for
example the paraxial mesoderm population is cultured at high cell density for about 0 to about 4 days,
optionally 0, 1, 2, 3, or 4 days before addition of TGFbeta3 agonist.
[00153] In an embodiment, the CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm
population is cultured with the TGFbeta agonist in serum free media for at least 3 days, or for about 3
days to about 14 days, optionally at least a week, to produce a Sox9+, collagen 2+ chondrocyte
precursor population.
As demonstrated herein, extended TGFbeta signaling can result in generation of an
articular like cartilage tissue. In an embodiment, the extended period of time the Sox9+, collagen 2+
chondrocyte precursor population is cultured with a TGFbeta agonist is at least 4 weeks, 5 weeks, 6
weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks or more to
produce an articular cartilage like tissue. In an embodiment, the chondrocyte precursor population is
cultured with the TGFb agonist until lubricin and/or cartilage intermediate layer protein 2 (CILP2) is
expressed. In an embodiment, the paraxial mesoderm population and/or the Sox9+, collagen 2+
chondrocyte precursor population is cultured with a TGFb agonist selected from TGFb3, TGFb2
and/or TGFb1.
Switching the culture from comprising TGFb agonist to BMP agonist, induces a
hypertrophic chondrocyte population that is growth plate like. In an embodiment, the hypertrophic
chondrocyte like cells and/or cartilage like tissue, is cultured with the BMP4 agonist to produce a
collagen 10+ and/or Runx2+ hypertrophic chondrocyte like cells and/orcartilage like tissue. In an
embodiment, the extended period of time the high cell density Sox9+ collagen2+ chondrocyte
precursor population is cultured with the BMP4 agonist, optionally BMP4 or GDF5, is at least 2 weeks,
3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13
weeks, 14 weeks or more to generate a cartilage tissue that expresses collagen 2 and/or a
hypertrophic chondrocyte population that expresses collagen 10.
For example, stage 3 can comprise a 2-3 day 'spotting' phase which can be done in
2% serum containing media, or serum free. This allows a high cell density of cells to adhere to a small
area for example of a tissue culture dish or membrane filter. At the end of this stage of optionally 3
days (+3 days), the majority and/or substantially all cells in the micromass express CD73, CD105, and
PDGFRbeta. In an embodiment, this step is followed by TGFB agonist treatment in serum free media
for a period of time that is optionally at minimum about 1 week (e.g. at +10 days, the culture is at day
). By about two weeks (from about 10 to about 14 days), early chondrocyte genes are expressed
such as Sox9 and Collagen 2. The cultures can either be maintained in TGFb agonist such as TGFb3
40 for example over a period of several weeks to several months to generate an articular cartilage (AC)
like tissue (e.g. stage 4). Upregulation of the AC gene lubricin is detected for example after about 5-
weeks of micromass culture.
Histological analyses over this extended period of time shows the generation of higher
quality tissue with longer culture, for example after 12 weeks compared to 6 weeks.
The generation of hypertrophic growth plate-like cartilage tissue is achieved by the
switching of TGFb agonist containing media to a media containing BMP4 agonist instead. The BMP4
agonist switch typically takes place at about day 25 after the cells have been stimulated with TGFb
agonist such as TGFb3 for at least 1 week. This switch causes the micromass cells to convert to a
hypertrophic chondrocyte phenotype, which is an enlarged cell (e.g. see Fig. 4C) that expresses
genes associated with growth plate differentiation (e.g. collagen 10 and Runx2).
[00159] It has been found that immediate stimulation with BMP4 at about 3 days of micromass
(when TGFb3 agonist is usually added) results in the micromasses balling up, becoming non-
adherent, and/or not surviving and/or making tissue. A switch to BMP4 anytime for example between
about 10 days and 6 weeks of stage 3 culture is able to induce this hypertrophic response in TGFb
agonist treated micromasses. In an embodiment, the switch to BMP4 agonist, optionally BMP4 is on
about day 25 to generate growth plate like cartilage.
Collagen 10 expression, indicative of growth plate hypertrophic chondrocytes is
expressed for example after several weeks (e.g. 9-12 weeks in the cell line in Example 1); similar
timing wise to lubricin in TGFb agonist treated micromasses. Thus, extended BMP4 agonist treatment
results in the generation of collagen 10 expressing growth plate-like cartilage tissue from hPSCs.
[00161] Accordingly, in an embodiment, the chondrocyte precursors are cultured in TGFbeta
agonist or BMP4 agonist for cartilage tissue formation.
The desired populations at one or more stages can be enriched. For example, the
CD73+ CD105+ cells and/or CD73+ PDGFR-beta+ can be isolated, optionally by flow cytometry, from
the paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta prior to
high cell density culture.
The methods described can also be used for example on chondrocyte precursor cells
that have been generated using other methods and/or that are isolated from a subject.
Accordingly, in another aspect described herein, the disclosure includes a method of
generating chondrocyte like cells comprising:
(a) culturing chondrocyte precursor cells at a high cell density, in serum free or serum
containing media;
(b) culturing the high cell density the chondrocyte precursor cells with a TGFbeta agonist
in serum free media; and
(c) either
(i) culturing the chondrocyte precursor cell with a TGFbeta agonist for an
extended period of time to produce an articular cartilage like chondrocyte
population; or
(ii) culturing the chondrocyte precursor cell with a BMP4 agonist for an extended
period of time to produce a hypertrophic chondrocyte population of cells
and/or cartilage like tissue.
In an embodiment, the chondrocyte precursor cells are primary fetal chondrocytes or
passaged fetal chondrocytes. In another embodiment, the chondrocyte precursor cells are primary
cells obtained from a subject with a cartilage or bone condition or disease. Cells obtained from a
subject can be subjected to methods to induce pluripotency prior to high cell density culture. For
example, primary chondrocytes can be isolated from patients and tested directly using the micromass
methods, or any somatic cell from a patient can be used to make patient specific IPS cells which
would then be differentiated using the 4 stages of the method described herein to generate cartilage
tissues. Cells obtained from a subject for example from a disease site can be used to test for
ameliorating drugs and/or cultured for example where the subject has osteoarthritis, with synovial fluid
components or other test substances to try to identify components that propagate and/or ameliorate
one or more symptoms. Cells or fluid components can also be obtained from a subject, for example
from a non-disease site and used to generate cells and/or tissue for autologous chondrocyte
implantation for example wherein the generated cells and/or tissues are administered to a subject. In
an embodiment, the cells are used for allograft transplantation.
[00166] The steps can be performed in vitro. Alternatively, cells and/or compositions
comprising the cells or tissue can be administered for example prior to full cartilage like tissue
formation to a subject and monitoring for cartilage formation in vivo. For example, cells prepared using
a method described herein and optionally dissociated prior to administration.
The methods can also be employed to generate a paraxial mesoderm population of
cells. In an embodiment, the method comprises:
(a) culturing a starting population of pluripotent stem cells with a primitive streak inducing
cocktail to induce a primitive streak-like mesoderm population expressing CD56 and
PDGFR-alpha;
(b) culturing a primitive streak-like mesoderm population with a paraxial mesoderm
specifying cocktail comprising:
(i) a FGF agonist;
(ii) a BMP inhibitor; optionally Noggin, LDN-193189, or Dorsomorphin; and
(iii) optionally one or more of a TGFbeta inhibitor, optionally SB431524; and /or
a Wnt inhibitor, optionally DKK1, IWP2, or XAV939;
to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and
PDGFR-beta.
In an embodiment the method further comprises enriching CD73, CD105 and/or
PDGFRbeta expressing cells.
[00169] In an embodiment, the concentration of a component (e.g. agonist, inhibitor, etc.) used
is an effective amount, for example effective to induce the expression of a marker indicative of the
desired cell type.
In an embodiment, the FGF agonist is a FGF.
In an embodiment, the concentration of FGF is any concentration between about 2
ng/ml to about 100 ng/ml, optionally about 20 ng/ml.
In an embodiment, the BMP inhibitor is Dorsomorphin (DM).
In an embodiment, the concentration of DM is any concentration between about 0.5
uM and about 5uM, optionally about 4 uM (e.g.micromolar).
In an embodiment, the TGFb agonist is TGFb1, 2 and/or 3.
[00175] In an embodiment, the concentration of TGFb1, 2 and/or 3 is any concentration
between about 1 ng/ml and about 50 ng/ml, optionally about 10 ng/ml.
Any number between a specified range includes for example every 0.1 or every 0.5
unit increment
In an embodiment, the concentration of TGFbeta3 is any concentration between
about 1 ng/ml and about 50 ng/ml, optionally about 10 ng/ml.
In an embodiment, the BMP4 agonist is BMP4.
In an embodiment, the concentration of the BMP4 is any concentration between
about 10 ng/ml and about 100ng/ml, optionally about 50 ng/ml.
Methods can also include a step of monitoring, optionally in vitro or in vivo, for
proteoglycan production, and/or calcification and/or mineralization, for example by Von Kossa
staining. For example von Kossa staining can be used to confirm mineralization and indicates the
development of growth plate like cartilage.
[00181] A further aspect of the disclosure includes a population of cells or tissue generated
using a method described herein, optionally for use for a utility described herein.
Accordingly provided is an isolated population of chondrocyte like cells, optionally
articular like non-hypertrophic chondrocyte like cells and/or cartilage like tissue and/or hypertrophic
chondrocyte like cells and/or cartilage like tissue, or precursor population generated according to a
method described herein.
In an embodiment, the isolated population is a paraxial mesoderm population
expressing cell surface CD73, CD105 and PDGFR-beta.
In an embodiment, the isolated population of chondrocyte like cells comprise cells
expressing one or more chondrocyte markers and/or genes, for example GDF5, WNT9A, and/or ERG
similar to joint interzone cells, lubricin Meox1 and/or CIP2 similar to articular chondrocytes, or RUNX2,
SP7, alkaline phosphatase (ALP/ALPL), and/or COL10A1 similar to hypertrophic chondrocyte cells.
A further aspect described herein is a composition comprising the population of
articular like non-hypertrophic chondrocyte like cells and/or cartilage like tissue and/or hypertrophic
chondrocyte like cells and/or cartilage like tissue, and/or precursor cells generated according to a
method described herein; and a carrier. Depending on the use, the carrier can be optionally
Polyethylene glycol (PEG), hydrogel, bone scaffolding, bone substitute scaffolding and/or matrigel.
Other carriers include for example carrier comprises one or more of a group consisting of sodium
hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS,
Dextran and polymers. For example, the carrier can be a carrier that is suitable for use in
transplantation applications e.g. pharmaceutical grade carriers. The carrier can also be suitable for
stabilizing the cells for transport and/or storage. Cells can for example be cryofrozen and/or tissues
can be shipped at room temperature and/or any between room temperature and about 4ºC.
The composition can for example be in a slurry comprising dissociated cells for
example for administration to a subject. In an embodiment, the composition can comprise other cells
for example endothelial cells and/or fibroblasts for example for growth plate cell/cartilage
transplantation.
A further aspect described herein includes a cartilage or bone tissue product
comprising cells and/or tissue described herein and a scaffold or membrane. For example, during
transplantation applications, chondrocytes can be administered to a damaged area in combination
with a membrane (e.g. tibial periosteum or biomembrane) or pre-seeded in a scaffold matrix. In an
embodiment, the scaffold is a bone substitute.
Cells and tissues generated according to the methods disclosed herein can for
example be used for ameliorating symptoms in a subject afflicted with a joint or bone disorder.
[00189] Another aspect described herein accordingly includes a method for ameliorating
symptoms and/or treating a subject in need thereof comprising administering the population of cells
and/or tissues described herein and/or inserting/implanting a product comprising said cells.
Uses of the cells, tissues and products are also provided in another aspect described
herein. In an embodiment, the disclosure provides use of the population of cells and/or tissues or
composition or product described herein for ameliorating symptoms and/or treating a subject in need
thereof.
In an embodiment, the population of cells for a use or method described herein for
example that are to be administered to the subject are induced from autologous cells.
In an embodiment, the population of cells is enriched for articular like non-hypertrophic
chondrocyte like cells and/or cartilage like tissue.
In an embodiment, the subject has a joint condition such as osteoarthritis,
osteochondritis dissecans, polychondritis, and other chondropathies, or joint injuries affecting the
cartilage.
In a further embodiment, the population of cells is enriched for hypertrophic
chondrocyte like cells and/or cartilage like tissue.
In yet another embodiment, the enriched hypertrophic chondrocyte like cells and/or
cartilage like tissue, is adhered to a scaffold or membrane.
In another embodiment, the subject has a bone condition such as a bone fracture,
bone break or is in need of a bone replacement for example due to a malignancy or trauma,
achondroplasia, osteogenesis imperfect, osteoporosis or other osteopathies.
The generated cells can be optionally immortalized and/or modified for example to
stably express a reporter gene operably linked to a promoter of a gene typically expressed in articular
chondrocyte like cells such as lubricin promoter and/or typically expressed in hypertrophic
chondrocytes such as collagen 10 promoter (e.g. reporter system) to provide a model cell, that can for
example be used for testing for candidate substances for their ability to promote, inhibit, maintain or
are active in articular chondrocytes or hypertrophic chondrocytes. A large number of reporter genes
are known in the art including for example fluorescent proteins such as GFP, RFP, dsRed etc,
luciferase. Reporter gene assays are versatile and sensitive methods and can be used to assay
numerous candidate substances in high-throughput drug-screening programs.
[00198] Also provided herein are kits comprising one or more of a cell or tissue generated
according to a method described herein, a product or composition comprising a cell or tissue
generated, optionally comprising a reporter system or other modification, according to a method
described herein, a combination of at least two selected from an agonist, inhibitor, media, apparatus
or other component that can be used in a method described herein and instructions for use for
40 example instructions on how to generate the cells, perform an assay or administer the cell, tissue,
composition, or product, and a vial or other container for housing one of these aforementioned cells,
tissues, compositions, products, agonists, inhibitors, medias etc.
The cells and tissues generated according to a method described herein can be used
for various applications. For example the cells and tissues can be used for predictive drug toxicology
and drug discovery. For example, a population of enriched hPSC-derived chondrocytes, articular or
growth-plate like, can be used in predictive drug toxicology screens as well as for screens aimed at
identifying novel compounds that impact chondrocyte biology and physiology. Drugs which promote
the proliferation, but also maintenance, of articular chondrocytes, optionally in the presence of one or
more disease mediators, will be of interest as expansion of primary articular chondrocytes from
patients in the past has led to the dedifferentiation of the chondrocytes to a mesenchymal like
phenotype, and results in less than ideal cartilage replacement.
Accordingly, an embodiment includes a method of testing a candidate chondrogenic
modulating substance, the method comprising:
a) contacting a test substance with a chondrocyte precursor lineage cell population, the test
substance contacted with the chondrocyte precursor lineage cell population at any step in the
method described herein;
b) assessing the effect of the test substance on chondrocyte proliferation, maintenance and/or
differentiation compared to a control population generated in the absence of test substance;
c) identifying the test substance as a candidate chondrogenic modulating substance if the test
substance increases or decreases proliferation, and/or affects chondrocyte maintenance or
differentiation compared to the control.
The modulating substance can for example be a disease mediator or a component
with protective activity. Disease mediators can also be used in the presence or absence of test
substances to screen for agents that inhibit and/or reduce the disease inducing effect of the disease
mediators.
The cells and tissues are optionally used for assessing cell transplantation protocols
ad may be used for cell transplantation. For example, these methods will allow for example
comparison of: a) the effects and efficiency of transplanting articular or growth plate like hPSC-derived
chondrocytes or cartilage tissues versus autologous chondrocyte transplantation or adult
mesenchymal stem cell-derived chondrocytes or cartilage tissues, b) the effects of transplanting
articular like cartilage tissues and/or a chondrocyte-cell-slurry to treat various articular cartilage
defects in animal models or patients with varying levels of joint disease including osteoarthritis, c) the
ability of hESC-derived growth plate-like chondrocytes or cartilage like tissues to be used for bone
regeneration (via a cartilage template intermediate).
40 [00203] The cells and tissues can for example be used in tissue engineering applications. For
example enriched populations of chondrocytes from hPSC cultures can be generated and used in
engineered constructs for example with defined proportions of chondrocytes and other cell types or
scaffolding. The hPSC-derived chondrocytes can be seeded for example onto a bone substitute, for
example, may allow for cartilage/bone interfaces in vitro, or in vivo. Such products can be
transplanted into patients or animals with damage to an osteo-chondral junction.
The methods can be used to establish patient-specific disease models (by generating
iPS cell lines from patients for example for diseases comprising a genetic component). Chondrocyte
like cell and tissue populations can be established from human patients using methods described
herein. In order to analyze the differentiation as well as the phenotypes of these diseased cells, a
paraxial mesoderm population can be generated and those cells can be specified to a chondrocyte
fate, and finally articular or growth plate like cartilage tissues using protocols described in this
disclosure.
The methods described herein can also be used to establish general models of
cartilage disease (e.g. hypertrophy) including those associated with osteoarthritis. Without wishing to
be bound by theory, BMP4 may be inducing a hypertrophic fate in articular-like chondrocytes and
cartilage tissues, which is a pathway which is often upregulated in articular cartilage at the onset of
osteoarthritis. As another example, the addition of factors isolated from osteoarthritis patients to
cultures described herein can be used to determine whether metabolically active compounds (such as
those found in the fat pad in the knee of OA patients) can affect the quality of the tissue in vitro.
Also, as CD73 has been found to identify articular chondrocyte like cells, the use of
CD73 by flow cytometry, and the quantitative measure of cell size indicating hypertrophy by flow
cytometry, can facilitate high throughput screening of factors which promote articular or growth plate
like fates, as well as histology of the tissue itself through marker based assessment methods.
Hypertrophy is associated with osteoarthritis for example in mouse models, and is thought to be
similarly causative in patients. These applications could for example be used to identify modulators of
hypertrophy.
[00207] In an embodiment, the candidate chondrogenic modulating substance is a factor
isolated from a subject with diseased cartilage or bone. In an embodiment the factor is isolated from a
fat pad in a joint, optionally a knee joint, of a subject with arthritis and/or obese or from healthy
subjects as controls. In another embodiment, the test substance is added with the BMP4 agonist and
the test substance is assessed for its ability to inhibit hypertrophy compared to controls treated in the
absence of the test substance. In yet another embodiment, hypertrophy is assessed using flow
cytometry, optionally by assessing forward and side scatter.
In another embodiment, the method comprises a method of assessing a candidate
articular chondrocyte proliferation inducer comprising:
(a) obtaining articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue
40 generated according to the method of described herein,
(b) culturing the articular like non-hypertrophic chondrocyte cells and/or cartilage like
tissue with a test substance;
(c) measuring the articular like non-hypertrophic chondrocyte like cell proliferation;
(d) detecting an increase in proliferation compared to articular like non-hypertrophic
chondrocyte cells and/or cartilage like tissue cultured in the absence of the test
substance indicating that the test substance is a candidate articular chondrocyte
proliferation inducer.
A further embodiment includes a method of assessing a candidate hypertrophic
chondrocyte proliferation inducer comprising:
(a) obtaining hypertrophic chondrocyte like cells and/or cartilage like tissue, generated
according to the method described herein,
(b) culturing the hypertrophic chondrocyte like cells and/or cartilage like tissue, with a test
substance;
(c) measuring hypertrophic chondrocyte, cell proliferation;
(d) detecting an increase in proliferation compared to hypertrophic chondrocyte like cells
and/or cartilage like tissue cultured in the absence of the test substance indicating
that the test substance is a candidate hypertrophic chondrocyte proliferation inducer.
In an embodiment, CD73 articular like non-hypertrophic chondrocyte cells and/or
cartilage like tissue are isolated prior to culture with the test substance, optionally isolated by flow
cytometry.
[00211] In another embodiment, the articular like non-hypertrophic chondrocyte cell and/or
hypertrophic chondrocyte like cell comprise a reporter gene functionally coupled to an articular
chondrocyte specific promoter (i.e. articular chondrocyte reporter system), optionally a lubricin
promoter element and/or a reporter gene functionally coupled to a hypertrophic chondrocyte specific
promoter, optionally a collagen 10 promoter element (i.e. hypertrophic chondrocyte reporter system);
and a compound that induces articular chondrocyte differentiation (identified by measuring the
articular chondrocyte reporter system activity) and/or a compound that induces hypertrophic
chondrocyte differentiation (identified for example by measuring hypertrophic chondrocyte reporter
system activity).
In an embodiment, an increase in proliferation is measured using one or more of the
following methods: a 3H Thymidine incorporation assay; a 5-bromo-2’-deoxyuridine (BrdU)
incorporation assay; and a propidium iodine assay.
A further embodiment includes a method of assessing AC cell and/or GPC cell
toxicity or protective activity of a test compound, comprising:
(a) generating articular like non-hypertrophic chondrocyte cells and/or cartilage like
40 tissue and/or GPC like cells and/or growth plate cartilage according to the method
described herein;
(b) culturing the articular like non-hypertrophic chondrocyte cells and/or cartilage like
tissue and/or GPC cells with the test substance;
(c) measuring cell toxicity and/or cell protective activity of the test substance;
(d) detecting an increase in cell toxicity compared to articular like non-hypertrophic
chondrocyte cells and/or GPC cells and/or tissue cultured in the absence of the test
substance indicating that the test substance is toxic to articular chondrocyte and/or
GPC cells or detecting an increase in protective activity (e.g. a decrease in cell
toxicity) compared to articular like non-hypertrophic chondrocyte cells and/or GPC
cells and/or tissue cultured in the absence of the test substance indicating the test
substance is protective.
[00214] In an embodiment, cell toxicity is measured using one of the following assays: a
Trypan blue dye assay; a luciferase assay; a tetrazolim salt conversion assay such as a MTT assay
and a WST-1 assay.
As demonstrated herein, IL-1beta can induce osteoarthritis like changes in a cartilage
cell population. Il-1b and other mediators, for example other cytokines and knee fat pad components
(e.g. disease mediators) as well as mechanical disruption can be used in screening methods
described herein. For example, cells produced using a method described herein can be contacted
with such disease mediators or mechanical disruption in the presence or absence of a test substance
(e.g. either added prior to the addition of the disease mediators or mechanical disruption or after the
cells have been contacted and/or mechanically disrupted to assess the test substances ability to
inhibit or reverse the disease mediator function.
In an embodiment, the AC like chondrocytes and/or cartilage like tissue or the
hypertrophic like chondrocytes and/or cartilage like tissue is/are contacted with a disease mediator
optionally prior to culture with the test substance.
In an embodiment, the disease mediator is a cytokine, optionally IL-1beta. In another
embodiment, the disease mediator is a joint fat pad component, optionally a knee fat pad component.
In an embodiment, the screening assay comprises one or more of the following
analyses or assays: histological analysis, biochemical assays such as those that quantify the
production of glycosaminoglycans and proteoglycans, gene expression analyses, gain/loss of a
fluorescent reporter such as lubricin or collagen 10 by microscopy or flow cytometry, gain or loss of
CD73 cell surface receptor expression, assays for cell death, and flow cytometry for cell size which
can indicate chondrocyte hypertrophy.
CD73 can be used as a positive selection marker for cell sorting experiments to
enrich for articular-like chondrocytes. These markers could facilitate the isolation of articular
chondrocytes from primary sources of tissue, to be used in conjunction with allogenic or autologous
40 cartilage repair strategies currently in use.
[00220] Accordingly a further aspect described herein includes a method of isolating articular
chondrocytes comprising: contacting a mixed population of cells comprising chondrocytes with an
antibody (or other binding molecule) that binds CD73 under conditions that allow for the formation of
an antibody(or other binding molecule):CD73 cell complexes; and isolating the antibody CD73 cell
complexes. This can be done by a number of known immunological methods known in the art
including cell sorting based methods.
In an embodiment the mixed population of cells comprises non chondrocyte cells,
non-articular chondrocyte like cells, and/or hypertrophic chondrocyte like cells.
In an embodiment, the antibody is coupled to a tag such as a bead such as a
sepharose bead or magnetic bead that for example facilitates isolation.
[00223] The combination of CD73, CD105, and PDGFR-beta can be used as positive
selection markers for isolating paraxial/chondrogenic mesoderm from other lineages or progenitors of
other lineages. As other lineages such as the cardiac lineage are often induced using similar
protocols to those used to generate paraxial mesoderm, isolation of paraxial mesoderm by cell sorting
using these cell surface markers provides a means to enrich for this population. For example, the cells
are enriched using flow cytometry.
Accordingly an embodiment includes a method of isolating paraxial chondrogenic
mesoderm population of cells comprising: contacting a population of cells comprising paraxial
chondrogenic mesoderm cells with a cocktail comprising a CD73 specific binding agent, CD105
specific binding agent, and a PDGFRbeta specific binding agent; and enriching for CD73+, CD105+
and PDGFRbeta+ cells. In an embodiment, the binding agent is an antibody. In another embodiment,
the cells are enriched using flow cytometry. Also provided is an isolated paraxial chondrogenic
mesoderm population of cells prepared according to the method described herein and which can be
comprised in a composition or in a product as described herein. These cells can also be used in
screening assays described herein. The paraxial mesoderm population can be used for example for
generating other cell types for example for generating skeletal muscle progenitors, adipocyte
progenitors (fat cells) and potentially bone progenitors (osteoblasts).
Further, the definitions and embodiments described in particular sections are
intended to be applicable to other embodiments herein described for which they are suitable as would
be understood by a person skilled in the art. Selections and combinations of different agonists,
inhibitors and/or other components including for example agonists, inhibitors, etc. recited in definitions
are also contemplated. For example, in the following passages, different aspects of the invention are
defined in more detail. Each aspect so defined may be combined with any other aspect or aspects
unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or
advantageous may be combined with any other feature or features indicated as being preferred or
40 advantageous.
[00226] The above disclosure generally describes the present application. A more complete
understanding can be obtained by reference to the following specific examples. These examples are
described solely for the purpose of illustration and are not intended to limit the scope of the
application. Changes in form and substitution of equivalents are contemplated as circumstances
might suggest or render expedient. Although specific terms have been employed herein, such terms
are intended in a descriptive sense and not for purposes of limitation.
The following non-limiting examples are illustrative of the present disclosure:
Examples
Example 1
Results
[00228] Chondrocyte formation in vitro includes the induction of a primitive-streak-like (PS)
population as embryoid bodies (stage 1), the specification of paraxial mesoderm in a monolayer
culture (stage 2), the generation of chondrocyte progenitors in high cell density micromass culture or
on collagen-coated membrane filters (stage 3), and the specification of articular and growth plate
chondrocytes and cartilage tissues in micromass or filter cultures (stage 4) (Fig. 1A).
[00229] A first step in differentiation from a pluripotent stem cell (PSC) state is the formation
of a PS population which, in the embryo, occurs during gastrulation when the three germ layers
(endoderm, mesoderm, and ectoderm) are formed. The PS population and endoderm and mesoderm
subsets can be induced from PSCs using a combination of Activin A (activin, a surrogate for Nodal),
Wnt, and BMP signaling molecules (Nostro, Cheng et al. 2008, Kattman, Witty et al. 2011, Craft,
Ahmed et al. 2013). A PS population induced with activin, BMP4 and bFGF can be observed by the
expression of cell surface markers CD56 and PDGF receptor alpha (PDGFRa) (Fig. 1B).
hESC derived primitive streak (PS) mesoderm expresses CD56, PDGFRalpha and
KDR, as shown in Figure 1C. hIPSCs were induced to a PS mesoderm population using Activin A (3
ng/ml), BMP4 (1 ng/ml), basic FGF (5 ng/ml) and CHIR99061 ( 1 micromolar), a small molecule Wnt
agonist during days 1 and 3 of induction. hIPSCs were induced for a two day period (day 1 to day 3)
instead of a three day period (day 1 to day 4) as in the case for the HES2 hES cell line (Figure 1C).
hIPSC-derived PS mesoderm also expresses CD56, PDGFRalpha and KDR (Figure 1D), however
these cell surface markers are not expressed if hiPSCs are induced in the absence of CHIR99061
(Figure 1E).
[00231] With no additional factors beyond day 4 of culture, progenitors contained within this
population, can be specified to a cardiogenic fate as observed by co-expression of the cell surface
markers KDR and PDGFRa at T5 (Fig. 2A, 0 DM, 0 FGF), and the subsequent expression of the
cardiac transcription factor Nkx2.5 on day 15 (T15) (Kattman, Witty et al. 2011), Fig. 2C).
To generate chondrocytes, it is essential to first specify this PS population to a
40 paraxial mesoderm fate. Previous studies have shown that mesoderm populations that express cell
surface markers often found on mesenchymal stem cells, CD73 and CD105, have chondrogenic
potential (Hwang, Kim et al. 2006). The expression of these two cell surface markers, as well as the
expression of transcription factors Meox1 and Nkx3.2 combined with the lack of expression of Nkx2.5
to monitor the emergence of a paraxial mesoderm population was used. Previous experiments in the
mouse ESC model system have shown the importance of inhibiting the BMP signaling pathway in the
context of FGF signaling to prevent the emergence of cardiac mesoderm and promote the
development of paraxial mesoderm (Craft, Ahmed et al. 2013). The addition of the inhibitor of type I
BMP receptors Dorsomorphin (DM) for a period of two days from T4 to T6 (days 4 to 6 of
differentiation) changed the expression patterns of PDGFRa and KDR by as early as T5, as the cells
expressed less PDGFRa than untreated mesoderm (Fig. 2A). The addition of bFGF did not change
the PDGFRa/KDR population drastically. Very few cells in untreated mesoderm conditions expressed
CD73 and CD105 (7.46%, Fig. 2B). Treatment with DM increased this population only slightly,
however, treatment with FGF from day 4 until day 15 increased the proportion of cells expressing
CD73 and CD105 dramatically (52%, Fig. 2B). The changes in expression of these surface markers
were accompanied by the upregulation of paraxial genes Meox1 and Nkx3.2 (Fig. 2C). Treatment with
both DM from T4-T6 and bFGF from T4-T15 resulted in a more robust CD73/CD105 population (67%)
and even higher expression of Meox1 and Nkx3.2 (Fig. 2C), suggesting that both BMP inhibition and
FGF treatment are required for paraxial mesoderm specification from the PS population. In addition to
CD73/CD105 expression, CD73-positive cells derived from FGF- or DM+FGF-treated monolayers
also expressed the PDGF receptor beta (PDGFR-beta, PBeta), suggesting that paraxial mesoderm
also expresses this cell surface marker (Fig. 2B).
During paraxial mesoderm specification in the monolayer culture, it was observed that
Wnt pathway inhibition (during the two day period after PS mesoderm induction (days 4 to 6 for hESC,
days 5 to 7 for hIPSCs)) resulted in an increase in the percentage of cells expressing the cell surface
markers CD73 and CD105 on day 15 of differentiation (Figure 2C). Thus, in some cell lines, the
efficiency of paraxial mesoderm specification may be improved in the presence of a Wnt pathway
antagonist immediately following the PS mesoderm induction phase.
Previous studies have shown that TGFBeta/BMP signaling is required to generate
chondrocyte progenitors from paraxial mesoderm. It has been found that TGFB3 (as well as
TGFbeta1 or TGFbeta2) stimulation is required for stage 3 (e.g. starting at day 15), as direct plating
of this mesoderm into BMP4 containing media resulted in the development of non-adherent cell
aggregates that did not form cartilage tissue. Following 10 days of TGFb3 treatment (day 25 total),
cultures could be switched to media containing BMP4 or maintained in TGFb3 (stage 4) in order to
specify subsets of chondrocytes (articular/non-hypertrophic or growth plate/hypertrophic). To
determine the chondrocyte potential of the day 15 mesoderm populations, the cells were plated at
40 high cell density in a 20 microliter volume on tissue culture treated Petri dishes for an hour
(micromass) and then the ‘spot’ was submerged/covered with media. In our initial studies, the cells
were ‘spotted’ in a media containing 2% fetal bovine serum. However, this short serum exposure can
be omitted with no effects on cartilage formation at later stages, making this protocol optionally serum-
free. After 2 to 3 days, serum-free media containing TGFb3 is added to the culture to generate
chondrocyte progenitors. Populations derived from the 4 different mesoderm (0 DM +/- FGF; 4 µM DM
+/- FGF) were tested in this micromass assay. While all four mesoderm populations adhered to the
dish (Fig. 2D) within 1 day of culture, different phenotypes were observed after 1 week. Contracting
(beating) cardiomyocytes, quantified by the expression of cardiac troponin T (cTnT) by flow cytometry
(Fig. 2E) were observed in micromasses derived from untreated mesoderm (0 DM, 0 FGF).
Mesoderm treated with DM alone did not remain adherent to form chondrocytes, but instead
aggregated in long strands that were washed away with media changes. FGF-treated, as well as
DM+FGF-treated cells survived the first week of micromass culture as an adherent layer of cells, and
did not generate any cardiomyocytes. After 4 weeks of micromass culture, cells treated in the
monolayer phase with DM+FGF generated cartilage-like tissues that could be observed by eye
(approximately 1 cm in diameter). Cells that were treated in monolayer phase with FGF alone did not
maintain a cartilage tissue phenotype, and detached from the culture dish (Fig. 2F). While both FGF-
treated and DM+FGF-treated monolayer cultures expressed similar levels of CD73/CD105/PDGFR-
Beta, the paraxial gene expression at day 15, as well as the overall survival of the cartilage tissue,
suggests that both BMP inhibition (here in the form of DM treatment) and FGF stimulation is required
to specify a paraxial mesoderm fate that has the potential to form cartilage-like tissues in-vitro.
To determine if CD73, CD105 and PBeta are expressed on the populations with
chondrocytes potential in the hESC differentiation cultures, CD73+CD105+ and CD73-CD105- and
CD73+PBeta+ and CD73-PBeta- fractions were isolated from DM+FGF-treated monolayers on day 15
and assayed in the micromass cultures (Fig. 3A). After 10 days in micromass the CD73+CD105+
cells and the CD73+PBeta+ cells adhered and survived. The double-negative cells in both
experiments failed to survive under these conditions (Fig. 3B). After two weeks, cartilage tissues
developed in the cultures derived from the CD73+CD105+ and CD73+PBeta+ sorted cells (either
maintained in TGFB3 or switched to BMP4-containing media). In contrast, the double-negative cells in
both cases failed to form any cartilage tissues (Fig. 3C). The differences in the potential to generate
cartilage tissue are shown in Fig. 3D. These data demonstrate that the CD73+CD105+PBeta+ cells
have the potential to generate chondrocytes and cartilage-like tissues, while cells lacking the
expression of these markers do not.
Access to the appropriate paraxial mesoderm population derived at the end of stage
2, and the generation of chondrocyte progenitors at the end of stage 3, provided an opportunity to
study the development of two subtypes of chondrocytes, articular chondrocytes (ACs) and growth
plate chondrocytes (GPCs). After the paraxial mesoderm cells are stimulated with TGFb3 for about 10
days, these chondrocyte/cartilage cultures can either be maintained in TGFb3 containing media or
switched to BMP4-containing media for several months (stage 4). TGFb3 or BMP4-treated cultures
40 form cartilage-like tissues over the course 12 weeks that can be analyzed histologically using stains
that indicate the presence of a cartilage-specific extracellular matrix (toluidine blue) and by the
expression of genes associated with either articular cartilage or growth plate cartilage.
Morphologically, chondrocytes found in TGFb3-treated cartilage tissues have a small fibroblastic-like
phenotype, while BMP4-treated chondrocytes are round with cobblestone-like appearance (Fig. 4A).
TGFb3-treated cartilage stain uniformly with toluidine blue contains small cells (chondrocytes)
dispersed evenly throughout the tissue (13 week old tissues, Fig. 4B). In contrast, the BMP4-treated
tissue contains enlarged hypertrophic chondrocytes. The remarkable increase in chondrocyte size in
BMP4-treated cartilage tissues may be indicative of chondrocyte hypertrophy, a normal process
involved with GPC differentiation. Hypertrophic chondrocytes in the growth plate in-vivo are marked
by collagen 10 expression. The growth plate differentiation program ultimately leads to cell death,
leaving a calcified matrix on which new bone can be formed. Hypertrophy was also observed in
BMP4-treated cartilage tissues by flow cytometric analysis using forward and side scatter plots of live
cells (Fig. 4C). TGFb3-treated chondrocytes form a tight population of smaller, less granular cells,
while BMP4-treated cells display a larger forward scatter (FSC), signifying larger cell size, as well as a
larger side scatter (SSC), signifying higher cell granularity at all time points assessed (3 week and 5
week micromasses are shown).
Histologically, TGFb3-treated cartilage tissue appears to have many of the same
characteristics of the future site of articular cartilage of fetal femurs aged 19 weeks (upper panel, Fig.
4D), while hypertrophic chondrocytes found in BMP4-treated cartilages resemble the appearance of
the growth plate chondrocytes found near the subchondral bone area of the fetal femur (lower panel).
These phenotypes suggest that cartilage tissues with characteristics of the two unique subtypes of
cartilage have been generated in-vitro from human PSCs. Primary fetal chondrocytes isolated from
the knee joint were also cultured in a micromass assay, identical to the protocol used for day 15
hPSC-derived paraxial mesoderm, and also generated cartilage tissue in-vitro. Histologically, TGFB3-
treated and BMP4-treated fetal chondrocyte derived cartilage tissues also look very similar to cartilage
tissues derived from hPSCs. Fig. 4E shows that replacing BMP-4 with GDF5 generates hypertrophic
chondrocytes similar to those in Fig. 4A.
Similar differences in cell size and morphology were observed in 12-week-old
cartilage tissues generated from hiPSCs with TGFbeta3 and BMP4. Tissues stained
metachromatically with Toluidine blue which indicates the presence of proteoglycans (Figure 4F). As
expected, type II collagen protein was present in hPSC-derived tissues generated under both
conditions (Figure 4G). Type X collagen was not detected in either tissue at this time point. Lubricin
protein was present in TGFbeta3- but not in the BMP4-treated micromass tissue (Figure 4H), and was
found preferentially in the flattened cells that line the top of the tissue structure. Taken together, these
findings provide strong support for the interpretation that sustained TGFbeta3 signaling promotes the
development of articular chondrocytes that can generate articular cartilage-like tissue, whereas BMP4
signaling induces the differentiation of hypertrophic (enlarged) chondrocytes that form cartilage with
growth plate characteristics.
40 [00239] The tissue generated under the two conditions was next analyzed for gene
expression patterns by qRT-PCR (Figure 5) and for the presence of specific proteins associated with
cartilage development by immunohistochemistry and immunostaining (Figure 4). Expression of
SOX9 and COL2A1, genes expressed by both articular and hypertrophic chondrocytes, was
upregulated by 2 weeks of culture in both TGFbeta3- and BMP4-treated tissues (Figure 5A-B). The
levels of expression were similar to those found in primary human fetal ACs, healthy adult ACs, and
iliac crest (hypertrophic) chondrocytes. Expression of genes associated with hypertrophic
chondrocytes including RUNX2, SP7, alkaline phosphatase (ALP/ALPL), and COL10A1 was
significantly higher in the 8- to 12-week old BMP4-treated tissue than in the tissue maintained in
TGFb3 (Figure 5C-F). The reverse pattern was observed for genes known to be expressed by
superficial zone articular chondrocytes including lubricin (PRG4) and cartilage intermediate layer
protein 2 (CILP2) (Figure 5G-H), as well as for those expressed in joint interzone cells, the progenitor
population of ACs, such as GDF5, WNT9A, and ERG (Figure 1-K).
[00240] Together, the histology and gene expression analyses of hPSC-derived cartilages
derived from TGFB3-treated cells and BMP4-treated cells suggest that two unique chondrocyte
populations and cartilage-like tissues have been generated in-vitro. The maturation of TGFB3-treated
cartilage tissues for an extended period of time (up to 12 weeks) allows for the expression of mature
AC genes, such as lubricin and CILP2. Treatment of the TGFB3 cultures with BMP4 induces a
hypertrophic response that is easily observed by histology and by the upregulation of genes
associated with hypertrophic chondrocytes found in the growth plate, collagen 10 and Runx2. Thus,
hPSC-derived cartilage tissue derived with TGFB3 treatment represents articular-like cartilage, while
BMP4-treated cartilage tissue represents growth plate-like hypertrophic cartilage.
In an effort to identify cell surface markers that can be exploited for the enrichment of
ACs either from hPSC differentiation cultures, or from cartilage tissue isolated from patients for the
purpose of autologous chondrocyte transplantation, we performed a flow cytometry based antibody
screen comprised of 350 antibodies. Several sources of primary chondrocytes from the knee joint
were screened, including at least two samples of human healthy adult articular cartilage that were
used for allogeneic transplantations, at least 4 human fetal chondrocytes aged 16-19 weeks of age,
and 1 sample of human adult chondrocytes isolated from the iliac crest in the hip area, which have
growth plate characteristics. From these screens, we identified CD73 as a marker of articular
chondrocytes (Fig. 6). CD73 is expressed by virtually all (>96%) of healthy adult articular
chondrocytes isolated from the knee, but it is expressed by only about 22% of iliac crest GPC-like
chondrocytes (Fig. 6A). CD73 is expressed by approximately half of fetal chondrocytes (Fig. 6B),
which may represent an impure population of articular chondrocytes as it is difficult to isolate just
these cells from the growth plate chondrocytes if the secondary ossification centre has not yet been
ossified, which happens during adolescence.
Primary (P0) and passaged (P2) fetal chondrocytes can also be cultured in
micromass with TGFB3 or BMP4, similar to how hPSC-derived cartilage tissues are formed. TGFB3-
40 treated fetal P0-derived or fetal P2-derived cartilage tissues contain over 93% CD73 positive cells,
while BMP4 treatment reduces the percentage of CD73+ cells to 70% and 61% respectively (Fig.
6C,D). CD73 expression is also expressed by over 98% of hPSC-derived cartilage tissues derived
with TGFB3-treatment (Fig. 6E). The percentage of CD73+ cells is reduced to only about 57% of cells
after BMP4-treatment. Thus, CD73 marks primary healthy adult ACs, a proportion of healthy fetal
chondrocytes, fetal chondrocytes or passaged fetal chondrocytes cultured as micromasses in TGFB3,
and TGFB3-treated articular chondrocyte-like cells derived from human PSCs.
It is interesting that a mesenchymal cell surface marker such as CD73 marks the
hPSC-derived paraxial mesoderm early in the differentiation as well as the end-stage articular-like
chondrocytes derived from that mesoderm. Paraxial mesoderm on day 12 (T12) and day 15 (T15)
expresses both CD73 and PDGFR-Beta, and after the three day ‘spotting’ phase (day 18 total), all
cells are CD73+PDGFR-Beta+ (Fig. 6F). Interestingly, both of these cell surface receptors are
downregulated after 10 days to 2 weeks of micromass culture. After 4 to 5 weeks, CD73 becomes re-
expressed in TGFB3-treated micromass cultures (Fig. 6G), suggesting that CD73 may become
expressed when the chondrocyte progenitors are differentiating toward the articular chondrocyte fate.
To further characterize the potential of the two types of chondrocytes, cells from
dissociated 8week-old tissue were injected subcutaneously into NSG immunodeficient mice. Both
populations generated proteoglycan-rich cartilage tissue that expressed type II collagen with no
evidence of mineralization by 4 weeks following transplantation. Distinct differences were observed in
the grafts after 12 weeks of transplantation. Tissues derived from BMP4-treated chondrocytes
retained little proteoglycan (Figure 7A, C) and contained areas of calcification/mineralization and
hypertrophy as revealed by positive von Kossa (Figure 7B) and type X collagen staining (Figure 7E),
respectively. Interestingly, grafts from the TGFbeta3-treated chondrocytes maintained a
proteoglycan- (Figure 7A, C) and type II collagen-rich ECM (Figure 7D) with no evidence of
calcification/mineralization or hypertrophy (Figure 7 B, E). The findings from these transplantation
studies demonstrate that the two chondrocyte populations are functionally distinct and provide
additional evidence that the TGFbeta3-treated cells represent articular chondrocytes as they generate
and maintain stable cartilage for over 12 weeks in vivo. Chondrocytes that developed in the
presence of BMP4, by contrast, display characteristics of those found in the growth plate, as they
gave rise to tissue that initiated endochondral ossification in vivo.
COL2A1, PRG4 (lubricin) and CILP2 were also upregulated in micromass tissues
treated with TGFbeta1 and TGFbeta2 for 12 weeks (Figure 8), indicating that the generation of
articular chondrocytes from hPSC-derived paraxial mesoderm response was not ligand specific.
[00246] Access to an unlimited supply of hPSC-derived articular-like cartilage provides an
opportunity to establish platforms to analyze the effects of pro-inflammatory cytokines such as
interleukin-1α (IL1beta), known to play a role in the early stages of osteoarthritis (OA). Treatment of
-week-old hPSC-derived ACs with IL1beta in the absence of TGFb3 for two weeks (Figure 9A)
resulted in the upregulation of expression of catabolic enzymes including matrix metallopeptidases 13
40 (MMP13) (Figure 9B) and MMP2 (Figure 9C), and ADAMTS4 & S5 (Figure 9D,E). These enzymes
cleave proteins found in cartilage extracellular matrix (ECM), such as collagens and aggrecans, which
leads to the degradation of cartilage tissue. Significant upregulation of MMP13 and ADAMTS4 was
observed only in the absence of TGFbeta3. ADAMTS5 was induced with or without TGFbeta3
present. The expression of lubricin (PRG4) and CILP2 was also downregulated when IL1beta was
added to tissues in the absence (Figure 9H-I) or presence of TGFbeta3. The addition of IL1beta also
led to a reduction in COL2A1 and ACAN expression (Figure 9F-G), an increase in vascular
endothelial growth factor (VEGF) expression (Figure 9J), and a noticeable loss of proteoglycans in the
tissue (Figure 9K). Together, these findings suggest that IL1beta signaling can initiate a transition
from an anabolic environment to a catabolic state in the hPSC-derived ACs, similar to that observed in
native cartilage during early OA pathogenesis.
Example 2
CD73+ cells represent articular non-hypertrophic chondrocytes, and the lack of CD73
positivity could identify growth plate-like hypertrophic chondrocytes.
Chondrocytes and cartilage-like tissues can be generated using a method described
herein for the example the method described in Example 1. Articular chondrocyte cells can be
isolated and/or separated from precursors or growth plate-like chondrocyte cells, using the CD73 cell
marker. As described herein, when AC-like cells are stimulated with BMP4 they become hypertrophic
and lose the expression of CD73 on their cell surface. A method of monitoring expression of the CD73
cell surface markers that can be used is the fluorescent-activated cell sorting (FACS) analysis.
Example 3
Use of hESC-derived chondrocytes or cartilage for drug toxicology screenings
HESC-derived chondrocytes obtained using a method described in herein for
example in Example 1 could be used for predictive drug toxicology screenings as well as drug
discovery. For example, the cartilage tissue and/or hypertrophic chondrocyte cells typical of growth-
plate-like cartilage tissue lineages as well as their precursors can be contacted with a test substance
and one or more biological endpoints measured such as cell death. For example, cell death can be
measured using for example a vital cell dye exclusion assay, such as the Trypan Blue assay. For
instance, AC-like chondrocytes which are exposed to a test substance (drug) can be monitored for
cell toxicity after desired time-points by counting the cells that are permeable to Trypan Blue dye.
Other assays include tetrazolim salt conversion assay. Examples of such assay include the MTT
assay as well as the WST-1 assay. The assay can be automated for high throughput screening.
Example 4
Use of hESC-derived chondrocytes or cartilage in testing cell proliferation as induced by test
substances
40 [00250] Another example of the use of hESC-derived chondrocytes is the testing of drugs that
have an effect on cell differentiation or proliferation. Of particular interest would be the testing of drugs
that can influence the proliferation of primary articular chondrocytes into articular cartilage tissue, as
monitored by the use of the CD73 marker which indicates an AC-like fate. A variety of cell proliferation
assays are available and can monitor response to a test substance of interest. For instance the H
Thymidine incorporation assay monitors the proliferation of cells after treatment with a test substance
or growth factor. Following such treatment, cells are incubated with H-thymidine for 16-24 hours. An
alternative assay is a 5-bromo-2’-deoxyuridine (BrdU) incorporation assay. Yet another alternative is
the use of the use of the propidium iodine test. The fluorescence is directly proportional to the DNA
content in the samples. This method of monitoring cell proliferation can be particularly useful in the
context of hESC-derived chondrocytes as it can be used with cells that are grown on a monolayer.
Example 5
Use of size and granularity of chondrocytes as a way to distinguish cell lineage
The disclosure describes methods for generating different lineages of chondrocytes,
more specifically the AC-like chondrocyte as well the growth-plate like chondrocytes. These lineages
can for example be distinguished based on size. For example, using the forward scatter (FSC-A) and
side scatter (SSC-A) of hESC-derived chondrocytes, in the absence of an antibody based staining
observed during flow cytometric analysis of live cells could be used. TGFB3 treated AC like cell
population displayed as a tight population of cells with generally uniformly size and granularity, while
BMP4-treated hypertrophic chondrocytes display a heterogeneous cell population that generally have
larger FSC-A and SSC-A attributes. Thus, FSC-A and SSC-A attributes of live cells can be a useful
readout in experiments where factors that induce or prevent chondrocyte hypertrophy are being
tested.
Example 6
Monitoring of cell development and cell lineage using reporter gene assays
A reporter gene assay can be used with the methods described herein to identify
factors and substances that maintain or alter the expression of chondrocyte specific genes including
mature cartilage genes such as lubricin or collagen 10. For example, a lubricin promoter- RFP (red
fluorescent protein) targeted hESC line could be used for screening test substances that induce
lubricin promoter activity and the expression of RFP detectable by fluorescent microscopy. An
increase in lubricin promoter RFP+ expression, fluorescence, or an increase in the percentage of cells
that express lubricin promoter RFP+ would indicate an increase in the percentage of cells that
displayed non-hypertrophic articular like chondrocyte characteristics. In contrast, a loss of lubricin
promoter RFP+ may indicate a loss of these cells and/or articular chondrocyte like characteristics.
40 [00253] Likewise, a collagen 10 reporter (such as collagen 10 promoter-Green Fluorescent
Protein - GFP) would be useful in detecting an increase or decrease in the level of collagen 10
expression in cartilage cells or tissues. An increase in collagen 10-GFP+ expression, fluorescence, or
an increase in the percentage of cells that express collagen 10-GFP would indicate an increase in the
percentage of cells that displayed hypertrophic chondrocyte characteristics. In contrast, a loss of
collagen 10-GFP may indicate a loss of hypertrophy.
The reporter lines can also be used in flow cytometry based screens.
Alternatively, a non-hypertrophic chondrocyte cell and/or hypertrophic chondrocyte
cell can be transiently or stably transfected with a reporter gene system where the reporter gene is
functionally coupled to an articular chondrocyte specific promoter (i.e. articular chondrocyte reporter
system), optionally a lubricin promoter element and/or a reporter gene functionally coupled to a
hypertrophic chondrocyte specific promoter, optionally a collagen 10 promoter element (i.e.
hypertrophic chondrocyte reporter system). The cells can be selected and then contacted with a test
substance. Test substances that induce articular chondrocyte differentiation can be identified by
measuring the articular chondrocyte reporter system activity (e.g. relative to a control) and test
substances that induce hypertrophic chondrocyte differentiation can be identified by measuring
hypertrophic chondrocyte reporter system activity (e.g. relative to a control).
While the present application has been described with reference to what are
presently considered to be the preferred examples, it is to be understood that the application is not
limited to the disclosed examples. To the contrary, the application is intended to cover various
modifications and equivalent arrangements included within the spirit and scope of the appended
claims.
All publications, patents and patent applications are herein incorporated by reference
in their entirety to the same extent as if each individual publication, patent or patent application was
specifically and individually indicated to be incorporated by reference in its entirety. Specifically, the
sequences associated with each accession numbers provided herein including for example accession
numbers and/or biomarker sequences ( e.g. protein and/or nucleic acid) provided in the Tables or
elsewhere, are incorporated by reference in its entirely.
CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION
Akiyama, H., M. C. Chaboissier, J. F. Martin, A. Schedl and B. de Crombrugghe (2002). "The
transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation
pathway and is required for expression of Sox5 and Sox6." Genes Dev 16(21): 2813-2828.
Archer, C. W., G. P. Dowthwaite and P. Francis-West (2003). "Development of synovial joints." Birth
Defects Res C Embryo Today 69(2): 144-155.
Blumer, M. J., S. Longato, C. Schwarzer and H. Fritsch (2007). "Bone development in the
femoral epiphysis of mice: the role of cartilage canals and the fate of resting chondrocytes." Dev Dyn
236(8): 2077-2088.
Burgess, R., A. Rawls, D. Brown, A. Bradley and E. N. Olson (1996). "Requirement of the
paraxis gene for somite formation and musculoskeletal patterning." Nature 384(6609): 570-573.
Bussen, M., M. Petry, K. Schuster-Gossler, M. Leitges, A. Gossler and A. Kispert (2004). "The T-box
transcription factor Tbx18 maintains the separation of anterior and posterior somite compartments."
Genes Dev 18(10): 1209-1221.
Craft, A. M., N. Ahmed, J. S. Rockel, G. S. Baht, B. A. Alman, R. A. Kandel, A. E. Grigoriadis
and G. M. Keller (2013). "Specification of chondrocytes and cartilage tissues from embryonic stem
cells." Development 140(12): 2597-2610.
Dao, D. Y., J. H. Jonason, Y. Zhang, W. Hsu, D. Chen, M. J. Hilton and R. J. O'Keefe (2012).
"Cartilage-specific ss-CATENIN signaling regulates chondrocyte maturation, generation of ossification
centers, and perichondrial bone formation during skeletal development." J Bone Miner Res.
Darabi, R., K. Gehlbach, R. M. Bachoo, S. Kamath, M. Osawa, K. E. Kamm, M. Kyba and R.
C. Perlingeiro (2008). "Functional skeletal muscle regeneration from differentiating embryonic stem
cells." Nat Med 14(2): 134-143.
Hirsinger, E., C. Jouve, J. Dubrulle and O. Pourquie (2000). "Somite formation and
patterning." Int Rev Cytol 198: 1-65.
Hwang, N. S., M. S. Kim, S. Sampattavanich, J. H. Baek, Z. Zhang and J. Elisseeff (2006).
"Effects of three-dimensional culture and growth factors on the chondrogenic differentiation of murine
embryonic stem cells." Stem Cells 24(2): 284-291.
Hwang, N. S., S. Varghese, H. J. Lee, Z. Zhang, Z. Ye, J. Bae, L. Cheng and J. Elisseeff
(2008). "In vivo commitment and functional tissue regeneration using human embryonic stem cell-
derived mesenchymal cells." Proc Natl Acad Sci U S A 105(52): 20641-20646.
Jukes, J. M., S. K. Both, A. Leusink, L. M. Sterk, C. A. van Blitterswijk and J. de Boer (2008).
"Endochondral bone tissue engineering using embryonic stem cells." Proc Natl Acad Sci U S A
40 105(19): 6840-6845.
Kattman, S. J., A. D. Witty, M. Gagliardi, N. C. Dubois, M. Niapour, A. Hotta, J. Ellis and G.
Keller (2011). "Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac
differentiation of mouse and human pluripotent stem cell lines." Cell Stem Cell 8(2): 228-240.
Kinder, S. J., T. E. Tsang, G. A. Quinlan, A. K. Hadjantonakis, A. Nagy and P. P. Tam (1999).
45 "The orderly allocation of mesodermal cells to the extraembryonic structures and the anteroposterior
axis during gastrulation of the mouse embryo." Development 126(21): 4691-4701.
Koyama, E., Y. Shibukawa, M. Nagayama, H. Sugito, B. Young, T. Yuasa, T. Okabe, T.
Ochiai, N. Kamiya, R. B. Rountree, D. M. Kingsley, M. Iwamoto, M. Enomoto-Iwamoto and M. Pacifici
(2008). "A distinct cohort of progenitor cells participates in synovial joint and articular cartilage
50 formation during mouse limb skeletogenesis." Dev Biol 316(1): 62-73.
Kramer, J., C. Hegert, K. Guan, A. M. Wobus, P. K. Muller and J. Rohwedel (2000).
"Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4."
Mech Dev 92(2): 193-205.
Kulesa, P. M. and S. E. Fraser (2002). "Cell dynamics during somite boundary formation
55 revealed by time-lapse analysis." Science 298(5595): 991-995.
LaPrade, R. F., L. S. Bursch, E. J. Olson, V. Havlas and C. S. Carlson (2008). "Histologic and
immunohistochemical characteristics of failed articular cartilage resurfacing procedures for
osteochondritis of the knee: a case series." Am J Sports Med 36(2): 360-368.
Lawrence, R. C., D. T. Felson, C. G. Helmick, L. M. Arnold, H. Choi, R. A. Deyo, S. Gabriel,
60 R. Hirsch, M. C. Hochberg, G. G. Hunder, J. M. Jordan, J. N. Katz, H. M. Kremers and F. Wolfe
(2008). "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States.
Part II." Arthritis Rheum 58(1): 26-35.
Lawson, K. A., J. J. Meneses and R. A. Pedersen (1991). "Clonal analysis of epiblast fate
during germ layer formation in the mouse embryo." Development 113(3): 891-911.
Mankoo, B. S., S. Skuntz, I. Harrigan, E. Grigorieva, A. Candia, C. V. Wright, H. Arnheiter and
V. Pachnis (2003). "The concerted action of Meox homeobox genes is required upstream of genetic
pathways essential for the formation, patterning and differentiation of somites." Development 130(19):
4655-4664.
Murakami, S., G. Balmes, S. McKinney, Z. Zhang, D. Givol and B. de Crombrugghe (2004).
"Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like
dwarfism and rescues the Fgfr3-deficient mouse phenotype." Genes Dev 18(3): 290-305.
Nakayama, N., D. Duryea, R. Manoukian, G. Chow and C. Y. Han (2003). "Macroscopic
cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells." J Cell Sci 116(Pt
): 2015-2028.
Nostro, M. C., X. Cheng, G. M. Keller and P. Gadue (2008). "Wnt, activin, and BMP signaling
regulate distinct stages in the developmental pathway from embryonic stem cells to blood." Cell Stem
Cell 2(1): 60-71.
Oldershaw, R. A., M. A. Baxter, E. T. Lowe, N. Bates, L. M. Grady, F. Soncin, D. R. Brison, T.
E. Hardingham and S. J. Kimber (2010). "Directed differentiation of human embryonic stem cells
toward chondrocytes." Nat Biotechnol 28(11): 1187-1194.
Pacifici, M., E. Koyama, Y. Shibukawa, C. Wu, Y. Tamamura, M. Enomoto-Iwamoto and M.
Iwamoto (2006). "Cellular and molecular mechanisms of synovial joint and articular cartilage
formation." Ann N Y Acad Sci 1068: 74-86.
Pelttari, K., E. Steck and W. Richter (2008). "The use of mesenchymal stem cells for
chondrogenesis." Injury 39 Suppl 1: S58-65.
Pelttari, K., A. Winter, E. Steck, K. Goetzke, T. Hennig, B. G. Ochs, T. Aigner and W. Richter
(2006). "Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal
stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID
mice." Arthritis Rheum 54(10): 3254-3266.
Singh, M. K., M. Petry, B. Haenig, B. Lescher, M. Leitges and A. Kispert (2005). "The T-box
transcription factor Tbx15 is required for skeletal development." Mech Dev 122(2): 131-144.
Steinert, A. F., S. C. Ghivizzani, A. Rethwilm, R. S. Tuan, C. H. Evans and U. Noth (2007).
"Major biological obstacles for persistent cell-based regeneration of articular cartilage." Arthritis Res
Ther 9(3): 213.
Tam, P. P. and S. S. Tan (1992). "The somitogenetic potential of cells in the primitive streak
and the tail bud of the organogenesis-stage mouse embryo." Development 115(3): 703-715.
Tanaka, M., V. Jokubaitis, C. Wood, Y. Wang, N. Brouard, M. Pera, M. Hearn, P. Simmons
40 and N. Nakayama (2009). "BMP inhibition stimulates WNT-dependent generation of chondrogenic
mesoderm from embryonic stem cells." Stem Cell Res 3(2-3): 126-141.
Tins, B. J., I. W. McCall, T. Takahashi, V. Cassar-Pullicino, S. Roberts, B. Ashton and J.
Richardson (2005). "Autologous chondrocyte implantation in knee joint: MR imaging and histologic
features at 1-year follow-up." Radiology 234(2): 501-508.
45 Umeda, K., J. Zhao, P. Simmons, E. Stanley, A. Elefanty and N. Nakayama (2012). "Human
chondrogenic paraxial mesoderm, directed specification and prospective isolation from pluripotent
stem cells." Sci Rep 2: 455.
Yamashita, A., R. Krawetz and D. E. Rancourt (2008). "Loss of discordant cells during micro-
mass differentiation of embryonic stem cells into the chondrocyte lineage." Cell Death Differ.
50 zur Nieden, N. I., G. Kempka, D. E. Rancourt and H. J. Ahr (2005). "Induction of chondro-, osteo- and
adipogenesis in embryonic stem cells by bone morphogenetic protein-2: effect of cofactors on
differentiating lineages." BMC Dev Biol 5: 1.
Claims (32)
1. A method for generating: articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both; or hypertrophic chondrocyte-like cells, cartilage-like tissue, or both; 10 the method comprising: a. culturing a CD56 and PDGFRα primitive streak-like mesoderm population generated from a pluripotent stem cell (PSC) population induced to differentiate into primitive streak-like mesoderm, with a paraxial mesoderm specifying cocktail comprising an FGF agonist selected from FGF2, FGF4, FGF9, FGF19, FGF21, FGF3, FGF5, FGF6, FGF8a, FGF16, FGF17, 15 FGF18, FGF20 and FGF23 for between 4-15 days following the induction of the PSC population wherein, from between 4-6 days following induction, the paraxial mesoderm specifying cocktail further comprises a BMP inhibitor selected from Noggin, LDN-193189, Dorsomorphin, Chordin, soluble BMPR1a, or soluble BMPR1b, to generate a CD73 CD105 , + + + + + CD73 PDGFRβ , or CD73 CD105 PDGFRβ paraxial mesoderm population; 20 b. culturing the paraxial mesoderm population at a high cell density with at least one TGFβ agonist selected from TGFβ3, TGFβ2, and TGFβ3 for at least 3 days, 3 to 7 days, or 3 to 14 days to produce a high cell density Sox9 , collagen 2 chondrocyte precursor population; c. either: 25 i. further culturing the high cell density Sox9 , collagen 2 chondrocyte precursor population with the TGFβ agonist in the absence of a BMP or PDGF agonist for at least 10 days to produce an articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both; or ii. further culturing the high cell density Sox9 , collagen 2 chondrocyte precursor 30 population with a BMP4 agonist selected from BMP4, BMP2, BMP6, BMP7 and BMP10 for at least 3 to 4 weeks to produce a hypertrophic chondrocyte-like cells, cartilage-like tissue, or both.
2. The method of claim 1, wherein the paraxial mesoderm specifying cocktail further comprises 35 one or more of a TGFβ inhibitor, wherein the TGFβ inhibitor is a molecule that inhibits the receptors ALK4 and ALK7 or TGF-3RI, and a Wnt inhibitor, wherein the Wnt inhibitor is a molecule that inhibits wnt/beta catenin receptor signaling. 5
3. The method of claim 1 for generating articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both, wherein step c) comprises culturing the high cell density Sox9 , collagen 2 chondrocyte precursor population with the TGFβ agonist in the absence of a BMP or PDGF agonist for at least 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks to produce articular-like non- hypertrophic chondrocyte cells, cartilage-like tissue, or both.
4. The method of claim 1 for generating hypertrophic chondrocyte-like cells, cartilage-like tissue, or both wherein step c) further comprises culturing the high cell density Sox9 , collagen 2 chondrocyte precursor population with the BMP4 agonist for at least 4, 5, 6, 7, 8, 9, 10, 11, or 12 weeks.
5. The method of any one of claims 1 to 4, wherein the paraxial mesoderm population is comprised in embryoid bodies or a monolayer culture.
6. The method of claim 1, wherein the pluripotent stem cell population is selected from: a) a 20 human embryonic stem cell population (hESC); b) an induced pluripotent stem cell population (iPSC); c) primary hESC; and d) primary iPSC.
7. The method of claim 6, wherein the hESC population is selected from a HES2 H1, H9, and any human iPSC cell line.
8. The method of claim 6 or 7, wherein the pluripotent stem cell population is aggregated into embryoid bodies.
9. The method of any one of claims 6 to 8, wherein the primitive streak-inducing cocktail further 30 comprises a Wnt agonist, wherein the Wnt agonist is Wnt3a or a selective inhibitor of GSK3b inhibitor in the Wnt signaling pathway.
10. The method of any one of claims 1 to 9, wherein the proportion of cells expressing CD73 or CD105 is increased by at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or 65% compared 35 to FGF agonist untreated cells.
11. The method of any one of claims 1 to 10, wherein cells in the paraxial mesoderm population also express transcription factors Meox1 and Nkx3.2, and are negative for Nkx2.5. 40
12. The method of any one of claims 1 to 11, wherein the paraxial mesoderm population is plated in a micromass culture, pellet culture or a filter culture or in any high cell density format. 5
13. The method of claim 12, wherein the paraxial mesoderm population is plated at a cell density between 10 million cells/ml and 20, 30, 40, or 50 million cells/ml, in a micromass culture; or between 500,000 cells and 750,000, 1 million, 1.25 million, 1.5 million, 1.75 million, or 2 million cells in a 12 mm diameter membrane filter culture. 10
14. The method of any one of claims 1 to 13, wherein the populations are cultured in serum free basal media comprising insulin, transferrin and selenium.
15. The method of claim 14, wherein the basal media comprises DMEM with insulin, transferrin, selenium supplement, proline, and dexamethasone.
16. The method of any one of claims 1 to 15, wherein the paraxial mesoderm population is cultured at high cell density for 0, 1, 2, 3, or 4 days before addition of the TGFβ agonist.
17. The method of any one of claims 1 to 3 and 5 to 16, wherein the TGFβ agonist is TGFβ3.
18. The method of any one of claims 1 to 3 and 5 to 16, wherein an articular cartilage-like tissue is produced by the articular like non-hypertrophic chondrocyte cells.
19. The method of claim 18, wherein the high cell density Sox9 and collagen 2 population is 25 cultured with the TGFβ agonist until at least one of lubricin or cartilage intermediate layer protein 2 (CILP2) is expressed.
20. The method of claim 1, wherein the hypertrophic chondrocyte-like cells, cartilage-like tissue, or + + + + both produced by the method are collagen 10 , Runx2 , or collagen 10 Runx2 .
21. The method of claim 20, wherein the hypertrophic chondrocyte cell population expresses collagen 10 or cartilage tissue that expresses collagen 2. + + + +
22. The method of any one of claims 1 to 21, wherein the CD73 CD105 , CD73 PDGFRβ , or + + + 35 CD73 CD105 PDGFRβ paraxial mesoderm population cells are isolated by flow cytometry prior to high cell density culture.
23. The method of claim 19, further comprising isolating a population of articular-like non- hypertrophic chondrocyte cells, cartilage-like tissue, or both. 5
24. The method of claim 23, further comprising combining the isolated population of articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both with a diluent, or a carrier selected from the group consisting of PEG, hydrogel, bone scaffolding and bone substitute scaffolding. 10
25. The method of claim 24, wherein the isolated population of articular-like non-hypertrophic chondrocyte cells is further combined with endothelial cells or fibroblasts.
26. A method of assessing a candidate articular chondrocyte proliferation-inducer comprising: e. obtaining articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both 15 generated according to the method of any one of claims 1 to 3; f. culturing the articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both with a test substance; g. measuring the articular-like non-hypertrophic chondrocyte-like cell proliferation; and h. detecting an increase in proliferation compared to articular-like non-hypertrophic 20 chondrocyte cells, cartilage-like tissue, or both cultured in the absence of the test substance indicating that the test substance is a candidate articular chondrocyte proliferation-inducer.
27. A method of assessing a candidate hypertrophic chondrocyte proliferation-inducer comprising: e. obtaining hypertrophic chondrocyte-like cells, cartilage-like tissue, or both, generated 25 according to the method of any one of claims 1, 2, and 4; f. culturing the hypertrophic chondrocyte-like cells, cartilage-like tissue, or both, with a test substance; g. measuring hypertrophic chondrocyte cell proliferation; and h. detecting an increase in proliferation compared to hypertrophic chondrocyte-like cells, 30 cartilage-like tissue, or both, cultured in the absence of the test substance indicating that the test substance is a candidate hypertrophic chondrocyte proliferation-inducer.
28. The method of claim 26, wherein a CD73 articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both is isolated prior to culture with the test substance, wherein the 35 CD73+ articular-like non-hypertrophic chondrocyte cells, cartilage-like tissue, or both is isolated by flow cytometry.
29. The method of any one of claims 2630 or 28, wherein the articular-like non-hypertrophic chondrocyte cells comprise a reporter gene functionally coupled to an articular chondrocyte 5 specific promoter, wherein articular chondrocyte differentiation is identified by measuring the articular chondrocyte reporter gene activity.
30. The method of claim 27, wherein the hypertrophic chondrocyte cells comprise a reporter gene functionally coupled to a hypertrophic chondrocyte specific promoter, hypertrophic 10 chondrocyte differentiation is identified by measuring the hypertrophic chondrocyte reporter gene activity.
31. The method of claim 26 or 27, wherein an increase in proliferation is measured using one or more of the following methods: a 3H Thymidine incorporation assay; a 5-bromo-2’-deoxyuridine 15 (BrdU) incorporation assay; a propidium iodine assay.
32. A method according to any one of claims 1, 26 or 27, substantially as herein described with reference to any example thereof and with or without reference to any one or more of the accompanying figures.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361809050P | 2013-04-05 | 2013-04-05 | |
US61/809,050 | 2013-04-05 | ||
PCT/CA2014/000312 WO2014161075A1 (en) | 2013-04-05 | 2014-04-02 | Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ713111A NZ713111A (en) | 2021-10-29 |
NZ713111B2 true NZ713111B2 (en) | 2022-02-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230330152A1 (en) | Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue | |
Jiwlawat et al. | Current progress and challenges for skeletal muscle differentiation from human pluripotent stem cells using transgene-free approaches | |
Bunnell et al. | Differentiation of adipose stem cells | |
Craft et al. | Specification of chondrocytes and cartilage tissues from embryonic stem cells | |
McCarthy et al. | The comparison of equine articular cartilage progenitor cells and bone marrow-derived stromal cells as potential cell sources for cartilage repair in the horse | |
Mauney et al. | Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion | |
Hoshiba et al. | Maintenance of cartilaginous gene expression on extracellular matrix derived from serially passaged chondrocytes during in vitro chondrocyte expansion | |
Nakayama et al. | Human pluripotent stem cell-derived chondroprogenitors for cartilage tissue engineering | |
WO2018062269A1 (en) | Method for producing somatic cell, somatic cell, and composition | |
JP2012228263A (en) | Feeder independent extended culture of embryonic stem cell | |
JP2013511987A (en) | Differentiation of human embryonic and induced pluripotent stem cells | |
US20230233617A1 (en) | Methods for differentiating stem cells into dopaminergic progenitor cells | |
Bukowska et al. | The importance of the canonical Wnt signaling pathway in the porcine endometrial stromal stem/progenitor cells: implications for regeneration | |
Waese et al. | One-step generation of murine embryonic stem cell-derived mesoderm progenitors and chondrocytes in a serum-free monolayer differentiation system | |
JP2023165901A (en) | Stepwise method of producing various types of cells from pluripotent stem cells | |
Zuba-Surma et al. | Sca-1 expression is associated with decreased cardiomyogenic differentiation potential of skeletal muscle-derived adult primitive cells | |
NZ713111B2 (en) | Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue | |
JP2024512385A (en) | Methods for generating oligodendrocyte progenitor cells and uses thereof | |
Kaur et al. | Neural stem cell assays | |
Diekman | Stem Cell-Based Strategies to Study, Prevent, and Treat Cartilage Injury and Osteoarthritis | |
SEONG | Differentiation and derivation of lineage-committed chondroprogenitors and chondrogenic cells from human embryonic stem cells for cartilage tissue engineering and regeneration |